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mTOR REGULATES AURORA A VIA ENHANCING PROTEIN STABILITY 
 
Mammalian target of rapamycin (mTOR) is a key regulator of protein 
synthesis. Dysregulation of mTOR signaling occurs in many human cancers and 
its inhibition causes arrest at the G1 cell cycle stage. However, mTOR’s impact 
on mitosis (M-phase) is less clear. Here, suppressing mTOR activity impacted 
the G2-M transition and reduced levels of M-phase kinase, Aurora A. mTOR 
inhibitors did not affect Aurora A mRNA levels. However, translational reporter 
constructs showed that mRNA containing a short, simple 5’-untranslated region 
(UTR), rather than a complex structure, is more responsive to mTOR inhibition. 
mTOR inhibitors decreased Aurora A protein amount whereas blocking 
proteasomal degradation rescues this phenomenon, revealing that mTOR affects 
Aurora A protein stability. Inhibition of protein phosphatase, PP2A, a known 
mTOR substrate and Aurora A partner, restored mTOR-mediated Aurora A 
abundance. Finally, a non-phosphorylatable Aurora A mutant was more sensitive 
to destruction in the presence of mTOR inhibitor. These data strongly support the 
notion that mTOR controls Aurora A destruction by inactivating PP2A and 
elevating the phosphorylation level of Ser51 in the “activation-box” of Aurora A, 
which dictates its sensitivity to proteasomal degradation. In summary, this study 
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is the first to demonstrate that mTOR signaling regulates Aurora-A protein 
expression and stability and provides a better understanding of how mTOR 
regulates mitotic kinase expression and coordinates cell cycle progression.  The 
involvement of mTOR signaling in the regulation of cell migration by its upstream 
activator, Rheb, was also examined. Knockdown of Rheb was found to promote 
F-actin reorganization and was associated with Rac1 activation and increased 
migration of glioma cells. Suppression of Rheb promoted platelet-derived growth 
factor receptor (PDGFR) expression. Pharmacological inhibition of PDGFR 
blocked these events. Therefore, Rheb appears to suppress tumor cell migration 
by inhibiting expression of growth factor receptors that in turn drive Rac1-mediate 
actin polymerization. 
Lawrence A. Quilliam, Ph.D., Chair 
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CHAPTER 1.  INTRODUCTION 
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1.1  mTOR and Cancer 
The Serine/Threonine kinase mammalian target of rapamycin (mTOR) is 
located at a critical point of convergence for the regulation of cell growth, 
differentiation, migration and survival [1, 2]. Dysregulation of mTOR signaling 
occurs in a diverse array of human cancers, including prostate, breast, ovarian, 
and brain tumors, which severely threaten human life [3, 4]. 
mTOR is known as mechanistic target of rapamycin or FK506 binding 
protein 12-rapamycin associated protein 1 (FRAP1), encoded by the FRAP1 
gene [1, 2]. Rapamycin is a specific mTOR antagonist that can block mTORC1 
downstream signaling. Rapamycin analogs such as CCI-779 and RAD001 have 
exhibited impressive growth inhibitory effects against a broad range of human 
cancers in preclinical studies [5]. A new generation of mTOR inhibitors, which 
compete with ATP for binding the catalytic site of the kinase, has demonstrated 
potent and selective inhibition to both mTORC1 and mTORC2 activities [6] [7]. 
 
1.2  mTOR in PI3K/PTEN signaling pathway 
The typical pathway of mTOR activation in signal transduction is via the 
PI3K/mTOR pathway.  
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Figure 1.1  PI3K/mTOR pathway, see text for details. 
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Following stimulation with growth factors such as platelet derived growth 
factor (PDGF), cellular membrane receptor tyrosine kinases are phosphorylated 
and activated, resulting in recruitment of their substrates to the cell membrane, 
where they become tyrosine phosphorylated. Subsequently, recruitment and 
stimulation of phosphatidyl inositol 3 kinase (PI3K) activity produces the 
phosphatidylinositol second messenger phosphatidyl inositol 3,4,5-trisphosphate 
(PIP3). PIP3 binds to the serine/threonine kinase AKT and recruits it to the cell 
membrane, where it is activated through phosphorylation of Thr308 by 
phosphoinositide-dependent kinase 1(PDK1) plus a second protein kinase 
phosphoinositide-dependent kinase 1(PDK2) that phosphorylates Ser473. 
Activated AKT phosphorylates the tuberous sclerosis complex 1 and 2 (TSC1/2), 
relieving the small GTPase Rheb from the inhibitory GTPase activating protein 
GAP activity of TSC2. ERK activity downstream of Ras can also phosphorylate 
TSC2, inhibiting its Rheb-GAP activity. Rheb-GTP in turn activates the Ser/Thr 
kinase mTOR, which phosphorylates and activates ribosomal S6 kinase 1(S6K1) 
and eukaryotic translation initiation factor binding protein 1(4E-BP1). S6K1 
regulates translation of TOP (5' terminal oligopyrimidine tract) mRNAs, which 
encode important components of the translation apparatus, while 
phosphorylation of 4E-BP1 promotes its dissociation from eukaryotic translation 
initiation factor 4E (eIF4E). The latter forms the initiation complex required for 
driving the 5’ cap-dependent translation of key cellular proteins including cyclin 
D1, Myc, and vascular endothelia growth factor. There is a negative feedback 
loop between S6K1 and insulin receptor substrate 1(IRS). S6K1-mediated 
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phosphorylation of IRS1 causes its destabilization, preventing the growth factor 
signaling to PI3K [8]. 
In addition to signals from growth factors that activate PI3K, it is 
anticipated that loss of the phosphatase and tensin homolog (PTEN) tumor 
suppressor, which is the phosphatase responsible for dephosphorylating the 
polyphosphoinositides generated by PI3K and is required for Akt activation, will 
also promote TSC2 down-regulation and subsequent activation of the 
Rheb/mTOR pathway. 
 
1.3  mTORC1 vs. mTORC2  
mTOR exists in two distinct complexes: mTOR complex 1(mTORC1) and 
mTOR complex 2 (mTORC2), which are different in their composition and 
substrate specificity [9]. mTOR complex 1 is composed of mTOR, a catalytic 
domain, mammalian lethal with Sec13 protein 8 (mLST8), proline-rich AKT 
substrate 40 kDa (PRAS40), DEP domain-containing mTOR-interacting protein 
(DEPTOR), and Raptor (regulatory-associated protein of mTOR)[9]. Raptor plays 
a role as a scaffold to present substrates to mTOR but does not alter kinase 
catalytic activity. PRAS40 is an inhibitory protein that blocks mTORC1 from 
binding substrates [11]. It is thought that Akt phosphorylation of PRAS40 at 
threonine 246 overcomes the inhibitory effect of PRAS40 on mTORC1 [12] [13]. 
The most characterized substrates of mTORC1 are initiation factor 4E-binding 
protein and S6 kinase 1. mTORC1 functions as a nutrient/energy/redox sensor 
and controls protein synthesis [3, 14, 15]. The activity of this complex is 
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stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids 
(particularly leucine), and oxidative stress [16].  mTORC1 is sensitive to 
rapamycin, from the S6K1 point of view. In the second part (Chapter 4) of this 
thesis, I will address mTORC1 activities on gene expression and protein stability 
for a particular kinase, Aurora A, in human cancer cells. 
mTOR complex 2 (mTORC2) contains mTOR, rapamycin-insensitive 
companion of mTOR (RICTOR), GβL, DEPTOR, and mammalian stress-
activated protein kinase interacting protein 1 (mSIN1) [14, 17]. mTORC2 is 
rapamycin insensitive, except following prolonged exposure (>24 hours) to the 
drug [5]. mTORC2 phosphorylates Akt at a serine 473 (S473) located  within a 
the C-terminal hydrophobic domain. Phosphorylation of this serine stimulates Akt 
phosphorylation at a threonine T308 residue by PDK1 and leads to full Akt 
activation. As such, mTORC2 appears to possess the activity of a previously 
elusive protein known as PDK2 [18] and as discussed in section 1.2. mTORC2 
has also been shown to function as an important regulator of the cytoskeleton 
through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and 
protein kinase C α (PKCα) [19]. Regulation of mTORC2 is less well understood 
than that of mTORC1; however, mTORC2 activity seems to be stimulated by 
growth factors through the PI3 kinase pathway [11, 20-22]. 
There is crosstalk between mTORC1 and mTORC2. For example, cells 
treated with rapamycin for short time (1-2 h) inhibits mTORC1 activity, while 
longer treatment increases Akt phosphorylation, an mTORC2 indicator, via IRS1 
degradation. Despite this breakthrough in the discovery of this feedback loop, the 
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complexity of this network is only just beginning to be understood. Recently, 
suppression of PI3 kinase was shown to decrease mTORC2 phosphorylation of 
Akt when cells were stimulated with growth factors insulin or insulin-like growth 
factors IGF in multiple cell lines [12, 13, 23], however details of the mechanisms 
still remain unclear. During the course of my thesis study, we encountered a 
similar question. That is, whether inhibiting mTORC1 activity would potentially 
increase mTORC2 function, in term of cell migration. In the first part (Chapter 3) 
of this thesis, I will address this issue. 
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1.4  Rheb as a molecular switch and upstream of mTORC1  
Ras-homolog enriched in brain (Rheb) is a ~21 kDa small GTPase. Like 
other members of the Ras superfamily, the activity of Rheb is regulated by a 
GTP-GDP cycle. A guanine nucleotide exchange factor (GEF) is speculated to 
promote release of GDP from Rheb so GTP can bind. Rheb is active when GTP 
is bound, and this induces a conformational change that permits interaction with 
downstream effectors. But Rheb becomes inactive following hydrolysis of the 
bound GTP to GDP. GTPase activating protein (GAP) accelerates the rate of 
GTP hydrolysis of GTPase. The tuberous sclerosis complex, a tumor suppressor 
formed by the tuberous sclerosis complex 1 and 2 (TSC1/2) proteins, functions 
as a GAP that stimulates Rheb GTP hydrolytic activity and hence acts as a 
negative regulator of Rheb [24]. Translationally controlled tumor protein (TCTP) 
has recently been identified as a putative guanine nucleotide exchange factor for 
Rheb in Drosophila and humans [15, 25], but this has been questioned in 
mammalian cell [26]. The Proud lab re-evaluated the role of TCTP as a GEF for 
Rheb and did not find any evidence to support the model of TCTP being a GEF 
toward Rheb [27] [28]. It is likely that inhibition of Rheb GAP activity through ERK 
and Akt-mediated phosphorylation of TSC2 or IkB-mediated phosphorylation of 
TSC1, rather than the activation of a GEF, promotes Rheb-GTP accumulation. 
Rheb GAP can be activated by AMP activated protein kinase (AMPK) and this 
overrides the above inhibitory kinases to promote Rheb inactivation during 
nutrient deprivation [29-31].   
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Figure 1.2  Rheb GDP-GTP cycle 
 
The activity of Rheb is regulated by its guanine nucleotide binding states via a 
GTP-GDP cycle. GAP promotes GTP hydrolysis to GDP. TSC1/2 proteins 
functions as a GAP that stimulates GTP hydrolysis of Rheb, so Rheb is 
inactivated. A possible GEF releases GDP from Rheb so GTP can bind, and this 
induces a conformational change that permits interaction of Rheb with 
downstream effectors. 
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Genetic and biochemical studies have placed Rheb upstream of mTOR 
and down-stream of TSC1/2 in the PI3K/Akt/TOR/S6K signaling pathway [24] 
[26]. Both GDP- and GTP-bound Rheb directly bind to the TOR kinase domain 
but only GTP-bound Rheb activates the TOR catalytic function [17, 32]. 
A key structural feature of Rheb is its C-terminal CaaX box. C is the 
cysteine that is prenylated, a is any aliphatic amino acid, and the identity of X 
determines which enzyme acts on the protein. Farnesyltransferase recognizes 
CaaX boxes where X = M, S, Q, A, or C and catalyze Rheb activity. 
Farnesyltransferase inhibitor (FTI), originally designed to block Ras-induced 
cancer, can suppresses Rheb activity, and consequently inhibit mTOR activity 
and cell growth [24, 33-35].  
Recent observations suggest that Rheb activates TOR by relieving an 
inhibitory interaction between TOR and FK506-binding protein 38 [18]. Very 
recently, it is thought that phospholipase D1(PLD1) also binds Rheb and can be 
activated by it [36, 37], but whether PLD1 also contributes to mTOR activation via 
generation of phosphatidic acid is not clear. 
Additional evidence to support the notion that Rheb is upstream of 
mTORC1 is that overexpressed Rheb can restore the TOR-dependent 
phosphorylation of S6K following amino acid withdrawal. Rheb has been shown 
to bind to mTORC1 and its accessory protein raptor to stimulate mTOR kinase 
activity responsible for cell growth and cell cycle progression in some tumors. 
The mTOR specific inhibitor rapamycin can block Rheb-induced transforming 
activity [38]. 
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An elegant work recently showed that specific activation of mTORC1 by 
Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. 
Activation of mTORC1 by Rheb involves enhanced binding of 4E-BP1. Raptor 
plays an important role in the activation of mTORC1 by Rheb. Rheb does not 
induce autophosphorylation of mTOR [39, 40]. 
 
1.5  Rho family and cytoskeleton reorganization 
Reorganization of the actin cytoskeleton is important in many cellular 
processes, including cell morphology change, cell adhesion and cell migration. 
Filamentous actin (F-actin) can be organized into four discrete structures - stress 
fibers, lamellipodia, membrane ruffles and filopodia. The Rho family, including 
ras homolog gene family member A (RhoA), ras-related C3 botulinum toxin 
substrate 1 (Rac1), and cell division control protein 42 homolog (Cdc42), control 
the actin cytoskeleton organization [41, 42]. RhoA mediates lysophophatidic acid 
-induced contractile stress fiber formation [43]. Rac1 is essential for growth 
factor-induced lamellipodia. Lamellipodia are thin protrusive actin sheets that 
dominate the edges of cultured cells, and membrane ruffles at the leading edge 
of cells are the result of lamellipodia that lift off the substratum and fold backward 
[44], while Cdc42 mediates bradykinin-promoted filopodia [42].  
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1.6  mTORC2 in Rho/Rac1-induced cell motility  
To date, little is known about the role of Rheb in regulating cell migration. 
However, Rac1 activates F-actin polymerization at the leading edge of cells, 
assembling fans, termed lamellipodia, allowing directed movement [37]. In the 
presence of growth factors, chemotaxis plays a central role in various biological 
processes, such as metastasis of cancer cells. Because only activated, GTP-
bound Rac can bind p21-activated kinase (PAK), use of PAK to pull down Rac-
GTP often is an approach to characterize active Rac1, and it can be used as a 
read-out for Rac1 activation. It is well established that Rac1 is activated 
downstream of receptor tyrosine kinases via multiple GEFs (independently of 
mTORC1) and Rac1 activation promotes actin polymerization [45-47]. Recent 
studies also reported that mTORC2 seems to function upstream of Rho GTPases 
to regulate the actin cytoskeleton. 
It was reported that mTORC2 may function as an upstream of Rho 
GTPases to regulate the actin cytoskeleton [46]. In mTOR, mLST8 or rictor 
siRNA-transfected cells, expression of constitutively active form of Rac1 (Rac1-
L61) or RhoA (RhoA-L63) restored organization of the actin cytoskeleton, 
indicating that mTORC2 may regulate the actin cytoskeleton through RhoA and 
Rac1. mTORC2 mediated, serum/ insulin induced actin polymerization is 
rapamycin insensitive in NIH 3T3 cells [46] 
Additionally, mTORC1 represses mTORC2 through feedback 
mechanisms, including inhibition of insulin signaling and platelet derived growth 
factor receptor (PDGFR) expression [31, 48]. Rapamycin treatment has been 
 13 
 
shown to relieve this inhibition leading to mTORC2 activation in multiple cancer 
cell lines [23]. Recent data have implicated the TORC2 kinase as the major 
hydrophobic kinase that phosphorylates Ser473 on Akt [49]. Elevated Akt kinase 
activity is found in a majority of glioblastomas (GBM) [50], in which mTORC2 
hyperactivated and promoted tumor cell proliferation and invasive potential. In 
contrast, shRNA-mediated inhibition of rictor expression reduces TORC2 activity, 
cell growth, and migration [49]. Whether Rheb is involved in these pathways to 
mediate Rac activation and cell motility in GBM cells will be addressed in chapter 
4.  
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1.7  mTORC1 signal and its substrates S6K1 and 4EBP1  
The best-characterized substrates of mTORC1 are 4E-BP 1and S6K1. 
mTORC1 phosphorylates S6K1 on a threonine residue (T389) [19][20]. This 
event stimulates the subsequent phosphorylation of S6K1 by PDK1 [20][21]. 
Active S6K1 in turn stimulate the initiation of protein synthesis through activation 
of S6 ribosomal protein (a component of the ribosome) and other components of 
the translational machinery [22]. 
In most cases, the rate of translation is regulated at the initiation phase, 
when a ribosome is recruited to the 5’end of an mRNA. The 4E-BP1 inhibits 
translation initiation by binding to the translation factor eIF4E, and prevent 
recruitment of the translation machinery to mRNA. The 4E-BP1 inhibits 
translation in a reversible manner. Hypophosphorylated 4E-BP1 interacts avidly 
with eIF4E,under stimulation of cells with hormones, cytokines, or growth factors, 
results in activating mTORC1, whereas hyperphosphorylated 4E-BP1 
consequently abrogates its eIF4E-binding activity, resulting in inactivating 
mTORC1.  
mTORC1 has been shown to phosphorylate at least four residues of 4E-
BP1, Threonine 37/46 (T37/46), Serine 65 (S65), and Threonine 70 (T70), in a 
hierarchical manner [51]. Phosphorylation on T37 and T46 are priming sites, 
followed by T70 phosphorylation and S65 last. However, phosphorylation of S65 
and T70 sites alone is not sufficient to disrupt 4E-BP1 binding to eIF4E. 
Therefore, I chose 4E-BP1 T37/46 phosphorylation status as markers for 
evaluation of mTORC1 activity in this study.  
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Besides controlling 4E-BP1 phosphorylation, mTOR also regulates protein 
synthesis by a distinct mechanism: mTOR phosphorylates and activates the 
ribosomal protein S6 kinase, which phosphorylates S6 ribosomal protein, a 
component of the S40 ribosome subunit, thus facilitating protein translation. 
Activated S6K initiates the translation of a class of mRNAs containing a tract of 
polypyrimidine (TOP) in their 5’untranslated regions (UTR) [52]. 
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1.8  mTOR inhibitors on S6K1 vs. 4EBP1  
Rapamycin was the first drug found to inhibit mTOR activity. Indeed, its 
anti-fungal and immunosuppressant actions were known prior to the subsequent 
identification of yeast TOR and its mammalian counterpart [53-56]. Rapamycin 
first forms a complex with the intracellular receptor FK506 binding protein 12 
(FKBP12) and then binds a domain distinct from the catalytic site of mTOR, 
blocking mTOR function. Rapamycin is highly specific for mTORC1, and its 
analogs are effective against certain types of cancer. These limited clinical 
successes led to researchers investigating the mechanisms of rapamycin action 
behind this failing. Firstly, rapamycin inhibits mTORC1, but not completely, which 
was demonstrated by rapamycin blocking S6K1, but not 4E-BP1 phosphorylation 
[55] [57]. My unpublished data supported this notion. Secondly, mTORC1 
inhibition often results in feedback activation of mTORC2 as well as other 
upstream growth and survival signals [58]. Third, rapamycin does not directly 
inhibit the mTORC2 complex whose activity is required for the growth of several 
types of cancer. Recent intensive efforts have focused on developing a new 
generation of mTOR inhibitors that includes Torin1 [59, 60], KU63794, and 
PP242 [6, 61]. These inhibitors inhibit both mTORC1 and mTORC2 activities. 
Compared with rapamycin, these ATP competitive inhibitors impaired the 
proliferation of primary cells to a far greater degree [6, 7]. At the beginning of 
their development, it was thought that the ability of PP242 and Torin1 to block 
cell proliferation more efficiently than rapamycin could be a result of inhibition of 
mTORC2 in addition to mTORC1. However, in MEFs genetically deficient for 
 17 
 
mTORC2 activity, rapamycin was also less effective at blocking cell proliferation 
than PP242 and Torin1. The data suggest that the potent inhibitory effect of 
PP242 and Torin1 on cell proliferation is a result of more complete mTORC1 
inhibition, but not a consequence of both mTORC1 and mTORC2 inhibition [60]. 
Consistently, both PP242 and Torin1 had much greater effects than rapamycin 
on 4E-BP1 phosphorylation and cap-dependent mRNA translation. These 
molecules competed with ATP in the catalytic site of mTOR, by demonstrating 
strong inhibition of both S6K1 and 4E-BP1 (mTORC1) and mTORC2 as well, 
showing high efficacy in the preclinical setting [6, 7]. Based on these drugs’ 
discovery during the period time of my research, I switched from rapamycin to 
using the ATP competitive inhibitors to study mTOR function in this thesis. 
 
1.9  mTOR in transcriptional regulation 
 TOR signaling is a prerequisite for the induction of ribosomal protein (r-
protein) gene transcription that occurs in response to improved nutrient 
conditions. This included the transcription of ribosomal RNA (rRNA) genes by 
RNA polymerase I (Pol I), transcription of ribosomal protein genes by RNA 
polymerase II (Pol II), and transcription of transfer RNA (tRNA) and 5S genes by 
RNA polymerase III [62, 63]. Recently, several studies identified a mammalian 
Pol I-specific transcription factor, transcription intermediary factor 1-alpha 
(TIF1A), whose activity is modulated by rapamycin. Mayer et al. [64] 
demonstrated that TIF-IA, an essential RNA Pol II transcription factor [63] is 
sufficient to rescue rapamycin-mediated inhibition of ribosomal DNA 
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transcription, demonstrating that mTOR plays a role in gene transcription. 
However, whether mTOR regulates Aurora A transcription is unknown. 
 
1.10  mTOR in translational regulation  
 
Figure  1.3  mTOR in translational regulation based on a figure from [29], see 
text for details. 
 
mTOR plays a critical role in translational regulation. Under most 
circumstances, the rate-limiting step in mammalian translation initiation is the 
binding of the ribosome to mRNA. Almost all of the factors involved in recruiting 
the ribosome, including eIF4E, eIF4B, and eIF4G, are phosphoproteins whose 
phosphorylation states are directly proportional to the translation and growth 
rates of the cell. In addition, the repressor proteins, 4E-BPs, are similarly 
phosphorylated under the same circumstances. Thus, increased phosphorylation 
of these factors in response to numerous extracellular stimuli correlates with 
 19 
 
released eIF4E, which enhances translation initiation rates and consequently 
increases translation of a subset of mRNAs.  
 
1.11  Two classes of translation models: complex 2nd structure vs. simple 5’ 
UTR mRNA 
Sonenberg and his colleagues proposed that the eIF4F complex functions 
to recognize the mRNA 5′ cap and unwind the mRNA 5’secondary structure. It 
has been postulated that the translation of mRNAs containing extensive 
secondary structure would be preferably stimulated by increased eIF4E activity 
[65]. eIF4E overexpression in cells enabled efficient translation of a reporter 
mRNA in which more secondary structure had been inserted in the mRNA 5’UTR 
. Indeed, eIF4E overexpression preferentially enhances the translation of mRNAs 
with structured 5′UTRs [66]. In contrary, dominant–negative eIF4A mutant 
proteins preferentially inhibit translation of these poorly translated mRNAs in vivo 
[67]. Additionally, eIF4B inactivation in yeast preferentially inhibits translation of 
reporter mRNAs possessing long and structured 5’ UTRs [68]. Subsequently, 
several groups identified mRNAs whose translation was preferentially stimulated 
in eIF4E-overexpressing NIH-3T3 cells as well as other cell lines. These mRNAs 
include, among others, ornithine decarboxylase (ODC), fibroblast growth factor 
(FGF), and vascular endothelial growth factor (VEGF). Two common features of 
these mRNAs are (1) a relatively long and structured 5’UTR, and (2) most 
importantly, their protein products function in controlling cell growth and 
proliferation. Hence, the translational activation of these mRNAs is expected to 
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promote cell growth and proliferation. ODC has been studied in some detail, as it 
is a model par excellence for studying translational control by eIF4E. It contains a 
G/C-rich 5’UTR of ∼300 nt and is not well translated in vivo or in vitro. In 
response to insulin stimulation, which activates eIF4E, its translation increases 
by ∼30-fold [66]. Consistent with these findings, the translation of ODC mRNA in 
eIF4E-overexpressing NIH-3T3 cells is also increased by ∼30-fold [67]. 
Experimentally induced elevation in the levels of other components of eIF4F and 
eIF4B would be expected to elicit similar effects.  
Recently Sabatini, et al [69] proposed an alternative model for the mRNA 
features and mechanisms that confer mTORC1-dependent translation control. In 
this model, the main class of mRNA molecules affected shortly after drug 
treatment contain short, unstructured 5ʹUTRs, in contrast to the highly structured 
5ʹUTRs previously reported. They used high-resolution transcriptome-scale 
ribosome profiling to monitor translation in mouse cells acutely treated with the 
mTOR inhibitor Torin 1, which, unlike rapamycin, fully inhibits mTORC1. They 
showed that the subset of mRNAs that are specifically regulated by mTORC1 
consists almost entirely of transcripts with established 5′ terminal oligopyrimidine 
(TOP) motifs, previously unrecognized TOP, or related TOP-like motifs. They 
found no evidence to support proposals that mTORC1 preferentially regulates 
mRNAs with increased 5′ untranslated region length or complexity. Rather, they 
mentioned that loss of just the 4E-BP family of translational repressors, the best 
characterized mTORC1 substrates, is sufficient to render TOP and TOP-like 
mRNA translation resistant to Torin 1. Further, the 4E-BPs inhibit translation 
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initiation by interfering with the interaction between the cap-binding protein eIF4E 
and eIF4G1. Loss of this interaction diminishes the capacity of eIF4E to bind 
TOP and TOP-like mRNAs much more than other mRNAs, during this 
translational program controlled by mTORC1, 4E-BPs and eIF4G1 are its master 
effectors [69]. 
Whether mTOR regulates Aurora A translation and by which of the above 
two models was addressed in this thesis. 
 
1.12  mTOR regulation of protein destruction 
mTOR, through regulating ubiquitin/proteasome activity, can modulate 
protein degradation. This has been noticed in several cases. For instance, 
mTORC2 targets Akt1 for protein degradation. Wu, et al showed that abolishing 
Akt Ser-473 phosphorylation stabilizes Akt following agonist stimulation [70]. The 
Akt Ser-473 phosphorylation promotes a Lys-48-linked polyubiquitination of Akt, 
resulting in its rapid proteasomal degradation. Blockade of this proteasomal 
degradation pathway with a proteasome inhibitor prolongs agonist-induced Akt 
activation. mTORC2 first stabilizes Akt protein folding through the Thr450 turn 
motif phosphorylation and then by promoting Akt protein degradation through the 
Ser473 hydrophobic motif phosphorylation, thus regulating the Akt protein life 
cycle [71, 72].  
mTOR also regulates cyclin D degradation. Rapamycin induces the 
ubiquitin-dependent APC system degradation of cyclin D1, accelerating the 
turnover of cyclin D1, which in turn reduces cyclin dependent kinase (CDK) 
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activation. This leads to depletion of active CDK4/cyclin D1 complexes, which 
may cause G1phase arrest. [73]. Whether mTOR affects Aurora A protein 
stability was examined in chapter 4 of this thesis.  
 
1.13  mTOR kinase suppression of PP2A protein phosphatase 
In Saccharomyces cerevisiae, TOR-mediated signaling activity promotes 
the interaction of phosphatase-interacting protein Tap42 with protein 
phosphatase 2A (PP2A) and 2A-like protein phosphatases. The distinct 
complexes formed between Tap42 and different phosphatases mediate various 
cellular events and modulate phosphorylation levels of many downstream factors 
in the TOR pathway in a TOR- and rapamycin-sensitive manner. Cell cycle-
dependent distribution of actin is an example [74]. 
In MDA-MB-231 human breast cancer cells, mTOR-dependent 
suppression of PP2A is critical for phospholipase D survival signals. Elevated 
phospholipase D activity suppresses the activity of the putative tumor suppressor 
PP2A in an mTOR-dependent manner [75].  
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1.14  Cell cycle 
The cell cycle is an ordered set of events, allowing inheritance of the 
genetic material from mother to daughter cells. It consists of four phases: G1 (cell 
growth), S (DNA synthesis), G2 (rapid cell growth and protein synthesis), and M 
phase (the chromosome separation, mitosis, and the cell division into two 
daughter cells, cytokinesis). Among these phases, mitosis is the most rapid and 
highly complex process. Within 1-2 hours, five mitosis phase; prophase, 
prometaphase, metaphase, anaphase and telophase, are completed. These 
processes are tightly controlled by several kinase families including Aurora 
kinases, cyclin-dependent protein kinases, and Polo-like kinases (Plk). Errors in 
the choreography of these processes can lead to aneuploidy or genetic 
instability, fostering cell death or coursing cancer. Thus, study of the 
mechanism(s) of mitosis regulation, particular its kinase proteins, may provide 
information to better understand cancer. 
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1.15  mTOR in G1 phase of the cell cycle  
 
 
Figure 1.4  Cell cycle based on a figure from Clinical Tools, Inc.  
 
Cell cycle includes phases G1, S, G2, and M (the nuclear division, mitosis and 
the cell division, cytokinesis). In the presence of unfavorable growth condition, 
cells may pause for extended periods in G1, or enter a prolonged non-dividing 
state, G0. 
 
 
 
1.15  mTOR in G1 phase of the cell cycle  
It is well-documented that mTOR signaling mediates G1 phase 
progression through regulation of gene transcription, mRNA translation, and 
protein destruction for certain genes such as p27kip, cyclin D1, and CDK4 in 
many cell types including human ovarian cancer cells [73, 76, 77] [78, 79].  
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1.16  TOR in G2/Mitosis progression 
Studies, primarily on lower eukaryotes, also suggested a role for mTOR in 
insulin delays the progression of fly cells through G2/M by activating G2/M 
progression. In fission yeast, increased nutrient provision transiently delays 
mitotic onset and blocks cell division, which relies upon TOR [80]. In Drosophila, 
the dTOR/dRaptor complex. dRaptor was found to be required for proper mitotic 
spindle assembly in Drosophila S2 cells. Mitosis specific raptor phosphorylation 
is required for normal cell growth and progression through G2/M of the cell cycle 
[81]. In mammalian cells, Liu et al.at 2007 first demonstrated that human S6K1 
phosphorylation and activity peak in M phase [82]. In oral squamous carcinoma 
and Hela cells, RT-PCR and immunoblot results showed that the level of mTOR 
mRNA did not change during the cell cycle, while the expression of p70S6K 
increased noticeably. Furthermore, activity assays in HeLa cells suggested that 
the activity of mTOR was maintained at a higher level in phase M than in any 
other phase [82].  
Another example is that the cell-cycle G2-M phase gene Ubiquitin-
Conjugating Enzyme E2C (UBE2C) was found overexpressed in various solid 
tumors. mTOR inhibitor CCI-779 inhibited UBE2C mRNA and protein expression 
reduction in RNA polymerase II loading to the UBE2C promoter, and attenuation 
of UBE2C mRNA stability, resulting in the cell-cycle G2/M accumulation [83]. 
Also, it is reported that Plumbagin, a cancer drug, inhibits cyclin B and Cdk1 
phosphorylation and destructs CDC25C protein via Akt mTOR, caused G2/M 
arrest [84]. 
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1.17  Introduction of Aurora family  
The Aurora kinase family is highly conserved among species, from 
Saccharomyces cerevisiae, Drosophila to Human [85]. Mutations in Aurora of 
drosophila and related Saccharomyces cerevisiae ploidy level 1 (Ipl1) kinase are 
known to cause abnormal chromosome segregation [86]. The mammalian Aurora 
family has three members: Aurora A, B, and C, all of which have a carboxyl 
terminal ‘‘destruction box’’ (D-box), however, Aurora A uniquely has an amino 
terminal ‘‘D-box-activating domain box’’ (A-box) [87, 88] required for the 
functional activation its D-box (Figure 1A). Though the majority of the structure is 
conserved, Aurora members’ functions are highly variable because of the 
differences in subcellular distribution and their activation levels during the cell 
cycle [89]. 
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Figure 1.5  Domains of Aurora kinases based on a figure from [88] 
Activation loop is required for kinase activity and typically is phosphorylated. A D-
box is found in many targets of the anaphase promoting complex including 
Aurora A, B and C kinases. Aurora A also has an A-box whose phosphorylation 
status regulates protein destruction [88]. 
 
Human Aurora A was originally identified by its close homology to 
Saccharomyces cerevisiae Ipl1. The latter was discovered in a screen for 
Saccharomyces cerevisiae mutations affecting chromosomal segregation [55, 
56]. Subsequently in 1995, Glover et al., identified the first allele for Aurora A in 
Drosophila mutants that were defective in spindle-pole behavior. The name 
Aurora is based on the aurora borealis, a phenomenon of the night sky in the 
polar region [57]. Human Aurora A, is also known as Aurora2, STK15, BTAK, and 
AIK. It is cell-cycle regulated, maps to chromosome 20, and is highly expressed 
in colon and breast and several other tumor types (5–7, 15). The full-length 
aurora A cDNA contains a 1209-bp open reading frame that encodes 403 amino 
acids with a predicted molecular mass of 46 kDa. The typical phenotype is 
monopole spindle, resulting from its failure of centrosome generation and 
separation in cells. 
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1.18  Transcription of Aurora A gene  
Transcription of the Aurora A gene (AURKA) is cell-cycle regulated. The 
promoters of the Aurora A gene contain specific elements cell cycle dependent 
(CDE)/cell cycle genes homology region (CHR), which are responsible for 
transcription at the G2 phase of the cell cycle [90]. However, the mechanism of 
transcriptional regulation is not fully understood. It was reported that AURKA 
mRNA level is mediated by transcription factors belonging to the E-twenty six 
(Ets) family, including epidermal growth factor (EGF), gamma-aminobutyric-acid 
receptor epsilon subunit precursor (GABP), and transcription factors responsible 
for adenovirus E4 gene transcription (E4TF1), which utilize the CDE and CHR 
promoter elements. AURKA mRNA expression is affected by its promoter 
interacting with activator-binding proteins, which vary during different stages of 
the cell cycle [90-92]. Hence, a wide range of variation is observed in the 
expression and activity of Aurora A during cell cycle progression [86, 91, 93]. In 
transformed cells which overexpressed EGF, transcription of Aurora A was 
increased via nuclear translocation of the EGF receptor. EGFR, upon 
phosphorylation at Thr845, is activated and binds to the promoter region of 
Aurora A, facilitating its transcription [94]. Together, this evidence provides the 
possibility that mTOR may regulate Aurora A mRNA expression and it was 
examined in chapter 3 of my study. 
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1.19  Translation of Aurora A  
The 5’ UTR of human AURKA mRNA has six alternative splicing variants 
that share a common open reading frame that is translated into a single common 
protein [95] (Figure 1.6). 
 
Figure 1.6  Six alternative splicings of AURKA 5’ UTR based on a figure from 
[95]  
Among the six variants, variant 1, 3, and 5 contain exon II, and variant 5 
reportedly responds to EGFR stimulation [95]. 
 
A cDNA representing variant 5 of the AURKA mRNA was cloned from 
human B cell library [86], the MDA-MB-231 breast cancer cell line [96] and colon 
cancer cell line [97], while variant 6 was discovered in testis cDNA cloning 
according to NCBI (National Center for Biotechnology Information) and in mixed 
and uncharacterized tissues from brain and liver. 
 A recent study showed that upon stimulation with EGF in colorectal cancer 
cell lines there was an increased the Aurora-A protein expression [95]. The 
overexpression of EGFR was associated with higher expression of Aurora A in 
 30 
 
clinical colorectal samples. Activation of the PI3K/Akt/mTOR and MEK/ERK 
pathways mediated the effect of EGF-induced translational up-regulation. 
Particularly, only the splicing variants containing exon 2 of Aurora A mRNA 
increased its interaction with the translational complex eIF4F to synthesize 
Aurora A proteins under EGF stimulus [95]. 
A more recent report illustrates that human pumilio homology protein 2 
(PUM2), an RNA-binding protein and a translational regulator, promotes both 
protein stability and kinase activity of Aurora A [98]. It was reported to bind to 5’ 
UTRs of mRNA and to repress gene expression by controlling cytoplasmic 
polyadenylation and affecting mRNA translation. Whether it is regulated by 
mTOR is unknown. 
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1.20  Aurora A protein destruction and ubiquitin/proteasome pathway  
In both low and high eukaryotes, Aurora A protein began to accumulate in 
G2 of the cell cycle and was stable throughout mitosis and rapidly disappeared in 
early G1[99]. Its degradation is mainly controlled by Anaphase-Promoting 
Complex (APC) ubiquitin/proteasome pathway.  
The ubiquitin/proteasome system is a major proteolytic system in the 
eukaryotic cell for selective destruction of proteins [100, 101]. This system 
contains an ubiquitin activating enzyme (E1), an ubiquitin conjugating enzyme 
(E2), and an ubiquitin ligase (E3). The 26S proteasome then degrades the 
ubiquitinated proteins [102-105]. 
The common feature of proteasome mediated protein degradation is the 
covalent attachment of ubiquitin to lysine residue of proteins targeted for 
degradation. Repeated addition of ubiquitin molecules to the substrate leads to 
the formation of polyubiquitin chains that are recognized by the 26S proteasome 
[106, 107]. In contrast to the E1 and E2 enzymes the E3 ubiquitin ligases display 
substrate specificity. The E3 enzyme for the ubiquitination of several mitotic 
proteins, including Aurora A, has been reported [108]. Anaphase promoting 
complex/cyclosome (APC/C), an E3 enzyme, is a large, multi-subunit ubiquitin-
protein ligase that catalyzes the attachment of ubiquitin to mitotic proteins, 
promoting their ubiquitin-dependent proteolysis. In eukaryotes, ubiquitination by 
APC/C is controlled by activator subunits that bind the APC/C core at different 
stages of the cell cycle. There are two activators, cell-division cycle protein 20 
(Cdc20) and Cdc20 homologue 1 (Cdh1). Cdc20 binds and activates the APC/C, 
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which triggers metaphase-to-anaphase transition by stimulating the destruction of 
regulatory proteins such as securin and cyclins that govern these events. While 
Cdh1 is primarily responsible for maintaining APC/C activity in later mitosis and 
throughout G1, it ensures some mitotic kinases such as Aurora A protein to be 
destructed and inactivated. The C-terminal D-box in Aurora-A is required for 
Cdh1-induced destruction, whereas the N terminal KEN-box is not. Destruction 
also requires an intact A-box, in which a conserved core consists of amino acids 
QRVL, a short stretch named D-Box-activating domain (DAD) located to the N-
terminus, whose deletion arrests the APC/C/Cdh1-mediated degradation [109-
112]. Briefly, APC/C/Cdh1 plays an important role in Aurora A protein stability 
and whether it is involved in mTOR-mediated Aurora A degradation will be 
investigated in chapter 3 of this study. 
As Cdh1 maintains APC/C activity in G1 phase [113-115] and Aurora A 
destruction was found in G1cell lysates [116, 117], it suggests that we can use 
asynthronized cells (~70-80% G1 population) for study degradation of Aurora A 
protein.  
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1.21  A-Box and D-Box of Aurora A required for Aurora A destruction 
 The APC/C/Cdh1 pathway predominantly regulates Aurora A levels at the 
time of mitotic exit. Full-length Aurora A requires both A-box and D-box for its 
Cdh1-dependent destruction and dephosphorylation of Ser53 during mitotic exit 
by protein phosphatase 2A (PP2A). This results in the conformational change in 
the D-box and in turn makes it more accessible for APC/C-mediated 
ubiquitination, and further exposes the A box for complete ubiquitination and 
degradation. Cdh1 recognizes the Arg378 of D-box. APC/C is more abundant 
during mitotic exit, which then targets Aurora A via its A-box and D-box sequence 
to the ubiquitin-dependent proteasomal degradation, as reported earlier [109, 
117-119].  
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1.22  Co-localization and interaction of Aurora A and PP2A 
 
 
Figure 1.7  Co-localization of Aurora A with PP2A-C at centrosomes during 
mitosis [119]. 
 
PP2A co-localized with Aurora A in prophase, metaphase, and anaphase cells. 
Aurora A is shown in red and PP2A catalytic subunit in green [119].  
 
The protein phosphatase PP2A is a member of the serine/threonine PP2 
phosphatase family. PP2A is a hetero-trimeric complex composed of three 
subunits: catalytic C subunit, structure A subunit, and regulatory B subunit. The 
former two subunits form a core dimer and interact with one of the several B-type 
regulatory proteins (B, B’, and B’’), which regulate the core dimer activity and 
substrate’s specificity. It was reported that PP2A affects numerous cellular 
functions, including signal transduction and cell cycle control. It was noticed that 
PP2A plays important roles in G2/M transition and mitosis completion. PP2A has 
also been proposed to play a role in the metaphase-anaphase transition in both 
 35 
 
yeast and mammalian cells. Recently, Andersen et al demonstrated that PP2A 
localizes to interphase centrosomes [119], which is known to be critical for 
mitosis initiation and progression, and the centrosomes contain key mitotic 
kinases such as Aurora A [88]. Importantly, PP2A physically interacts with Aurora 
A during mitosis in human cells and is inhibited by a phosphomimetic peptide 
containing S51 in the A-box of the Aurora A. Therefore PP2A appears to regulate 
Aurora A protein stability. In chapter 3, I will address whether mTOR regulates 
Aurora A via this phosphatase.  
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1.23  Aurora A in mitosis of the cell cycle 
 
 
Figure 1.8  Aurora A in mitosis of the cell cycle based on a figure from [120] 
 
Aurora A facilitates mitotic entry and is essential for centrosome separation and 
bipolar spindle formation. Aurora A is also involved in the process of mitotic exit 
during the cell cycle [88].  
 
Aurora A kinase is intimately involved in several essential steps of the cell 
cycle, such as mitotic entry, centrosome duplication, separation, and maturation 
[121] as well as bipolar spindle assembly [122], chromosomal alignment, 
cytokinesis, and mitotic exit [88]. Dysregulation of Aurora A expression and 
activity leads to centrosomal as well as spindle assembly checkpoint defects, 
aneuploidy, genetic instability, transformation, and tumorigenesis. 
Mitotic entry: One substrate of aurora A is Cdc25B, a direct regulator of 
the cyclin B1-Cdk1 complex, which provides the basis for the role this enzyme 
plays in regulating entry into mitosis [123]. Aurora A regulates centrosome 
maturation by moderating the recruitment of proteins, such as TPX-2, Ajuba, 
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Bora and Lats, which are essential for accumulating microtubule spindle 
components, such as gamma-tubulin. Aurora A is also associated with 
separation of centrosomes, through phosphorylation of the kinesin motor protein, 
Eg5. In addition, this enzyme regulates the microtubule network that forms 
mitotic spindles, through regulation of the EXTAH multiprotein complex. One of 
the characteristic features of Aurora A inhibition is monopolar spindle formation 
and cell cycle arrest [122]. 
 
Figure 1.9  Cell lacking Aurora A forms a monopolar chromosome [122] 
 
Image of murine embryonic fibroblast cells following knockout of AURKA shows a 
surrounding circular chromosome array, called monopolar chromosome. The 
chromosomal DNA was stained with DAPI [122].   
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1.24  Aurora A in tumorgenesis 
 
 
Figure 1.10  Aurora A in tumorigenesis based on a figure from [88] 
 
Aurora A is overexpressed in many cancers by several mechanisms, including 
gene amplification, elevated transcription as well as suppression of protein 
degradation. Overexpression of Aurora A leads to abnormal spindle formation 
and cytokinesis failure. Polymorphism of the Aurora A gene can also contribute to 
tumorigenesis by abrogation of its normal mitotic regulatory functions. Aberrant 
phosphorylation of the kinase substrates by hyperactive Aurora A are also a 
probable cause of carcinogenesis [88]. 
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Aurora A is overexpressed in cancers by several mechanisms, such as 
gene amplification, enhanced transcription, as well as suppression of protein 
degradation. Overexpression of Aurora A leads to abnormal spindle formation 
and cytokinesis failure. Subsequently, aneuploidy succeeds polyploidy which, in 
the absence of a functional p53-Rb pathway, results in amplification of 
centrosome number and chromosome instability. Polymorphism of Aurora A 
gene can also contribute to tumorigenesis by abrogation of its normal mitotic 
regulatory functions. Aberrant phosphorylation of substrates by hyperactive 
Aurora A could also be a probable cause of carcinogenesis [88]. 
Aurora A acts as an oncogene by phosphorylating various substrates. 
Most of these are associated with either centrosome associated or spindle 
assembly related protein. The approximately 26 known substrates of Aurora A 
protein kinase include: Centrosomin, CENP-A, p53, IkBa, cdc25B, Plk1, and Eg5 
[88]. 
CDC25B: As early as 2000, cell division cycle 25 homolog B (Cdc25B), a 
CDC25 phosphatase, was identified as a substrate of Aurora A. Aurora A 
phosphorylates Cdc25B at Ser353, which then localizes at the centrosome. 
Aurora A recruits Cdk1/Cyclin B1 to the centrosome prior to onset of mitotic 
events. So Aurora A is upstream of the Cdc25B phosphatase as well as the 
Cdk1/Cyclin B1 complex for commitment of mitotic entry [88] [124].  
CENP-A: Aurora A phosphorylates centromere protein A (CENP-A) at the 
amino-terminal serine 7. This phosphorylation is important for the proper 
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attachment of microtubules to the kinetochore and consequently for chromosome 
alignment and segregation [94, 125] 
Plk: Polo-like kinase is another mitotic kinase that localizes to the 
centrosome. It has functions that are quite similar to Aurora A that aid in bipolar 
spindle formation. In the presence of Aurora A-binding protein, Bora, Plk1 
activation occurs upon phosphorylation of Thr210. Phosphorylation of this site is 
mediated by Aurora A during G2/M transition, and maintained until cells enter 
into mitosis [88, 126].  
p53, a well-known protein 53 tumor repressor, is also a substrate of 
Aurora A. There are two Aurora A phosphorylation sites identified on p53. Aurora 
A directly phosphorylates p53 at Ser315, which augments p53 and Mdm2 
interaction. This facilitates ubiquitination and mdm2-mediated degradation of p53 
in cancer cells [127]. Another Aurora A phosphorylation site is Ser215, within 
p53’s DNA-binding domain. Phosphorylation of Ser215 by Aurora A enables 
inactivation of p53’s by DNA-binding and transactivation activity. As a result, p53 
target genes p21 and PTEN are down-regulated, and p53 tumor suppressor 
activity is inhibited by Aurora A [88, 127-129] 
IkBα: an nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor alpha, similarly Aurora A kinase-mediated IkBα phosphorylation 
determines the stability of this protein. Upon phosphorylation of the residues 
Ser32 and Ser36, IkBα gets degraded leading to the activation of NFkB. As a 
consequence, NFkB is free to translocate to the nucleus and thus can activate 
transcription of is downstream targets [88, 130].  
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BRCA1: Potential roles of Aurora A in cell transformation were also 
demonstrated from recent studies that this kinase phosphorylates a breast 
cancer tumor suppressor BRCA1 at Ser308 [14]. Both proteins are localized on 
the centrosome at the beginning of mitosis [15], suggesting that signaling 
between these two proteins are crucial for regulation of a normal cell cycle. 
Aurora A is overexpressed in a wide range of human cancers.  It maps to 
chromosome 20q13.2, a region that is frequently mutated in human cancers. 
There are numerous reports showing significant incidence of Aurora A 
amplification and overexpression in human breast, bladder, ovarian, colon, and 
pancreatic cancers. 
There are several mechanisms by which Aurora A promotes 
tumorigenesis: Aurora A overexpression causes checkpoint defect and genome 
instability; Aurora A overexpression in polyploidy is linked to cancer; Aurora A 
overexpression results in extra copies of centrosomes in cell lines as well as in 
rat mammary models. However, centrosome amplification observed in the cells 
overexpressing Aurora A was not due to centrosome duplication, but as a 
consequence of cytokinesis failure and multinucleation. Disruption of the normal 
centrosome duplication cycle results in the formation of monopolar or multipolar 
spindles leading to polyploidy, which is a precursor of aneuploidy and contributes 
to carcinogenesis.[88]. 
In summary, mTOR-regulated protein expression potentially impacts G2/M 
progression. Since Aurora A is an important mitotic kinase that plays crucial roles 
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in mitotic progression and tumorigenesis it has been examined in this thesis as a 
potential mediator of mTOR action.  
 
RESEARCH OBJECTIVES 
mTOR is a key regulator of protein synthesis that is inhibited by the 
macrolide antibiotic, rapamycin. Rapamycin has been shown to cause arrest of 
cells in G1 phase of the cell cycle. However, whether mTOR regulates mitosis is 
uncertain. Since G2/mitosis progressions are important for cell division, I will 
focus on whether mTOR regulates the expression and/or activity of key proteins 
that control G2/mitosis. These studies may provide a better understanding of how 
mTOR coordinates cell cycle progression and protein synthesis for cell growth 
and proliferation.  
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CHAPTER 2.  MATERIALS AND METHODS  
  
 44 
 
2.1  Materials 
Rapamycin (FRAP/mTOR inhibitor) from Cell Signaling. Torin 1 from 
TOCRIS; Ku-0063794 (KU63794) from Selleckchem; PP242 from BioVision; 
Proteasome inhibitor MG132 10 mM stocks in dimethyl sulfoxide (DMSO) were 
purchased from Calbiochem; okadaic acid (OA) from Sigma. Plasmids 
pcDNA3.1-Flag-Aurora A S51A and Flag-Aurora A S51D were gifts from Takashi 
Takata in Japan. 
 
2.2  Cell culture and cell cycle synchronization 
HeLa cells were obtained from ATCC and cultured in RPMI-1640 
supplement with 25 mM L-Glutamine and 10% fetal bovine serum (FBS) 
(Hyclone). HEK293T cells were cultured in DMEM (BioWhittaker) supplemented 
with 10% FBS. The cells were maintained at 37°C with 5% CO2. 
For synchronization, double thymidine blockage/release approach was 
employed [86]. HeLa cells were seeded at 100,000 cells per well in a 6-well 
plate. The following day, thymidine (Sigma) was added to the media to a final 
concentration of 2.5 mM and the plates were incubated for 16 hours at 37°C. The 
plates were then washed three times with phosphate-buffered saline (PBS) and 
normal growth medium was added. Following 8 hours at 37°C, cells were treated 
with thymidine for additional 16 hours. To release them from the drug treatment, 
cells were washed with PBS three times and normal growth medium was added. 
For monitoring mTOR effects on G2/M phases, mTOR inhibitor KU63794 1μM 
was administrated at indicated times.  
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2.3  Cell lysates preparation and immunoblotting analysis 
HeLa cells were lysed in 50 mM HEPES, pH 7.5, 500 mM NaCl, 6 mM 
MgCl2, 0.2 mM Na3VO4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.05% 
SDS, 19 μg/ml aprotinin, and1 mM phenylmethylsulfonyl fluoride. Lysates were 
centrifuged at 10,000 rpm at 4oC for 10 minutes and the soluble components 
were then collected into 1.5-ml tubes. Protein concentrations were determined 
using a Bio-Rad protein quantitation kit according to the manufacturer’s 
instructions. Equal amounts of proteins were separated by SDS-polyacrylamide 
gel electrophoresis using 4-20% gradient Tris-Glycine gels (Invitrogen) and 
proteins were then transferred to PVDF-FL membranes (Millipore). Transferred 
membranes were then incubated in TBS-T solution containing 20 mM Tris-HCl 
(pH 7.9), 150 mM NaCl, and 0.2%Tween 20 supplemented with 5% nonfat milk, 
followed by incubation with the primary antibody specific to indicated protein. 
Antibodies specific to Aurora A/AIK(1G4) were obtained from Cell Signaling, 
glyceraldehyde-3-P dehydrogenase (GAPDH) from Biodesign, M2 anti-FLAG 
from Sigma, Histone H3 and Histone H3 Ser10 from Millipore, S6K1 and S6K1 
Thr389, 4E-BP1 and 4E-BP1 Thr37/46, Ser65, and Thr70, Cdc2 (Cdk1) were 
from Cell Signaling. The membranes were incubated in TBS-T containing 5% 
nonfat milk over night at 4oC. The membranes were then washed three times in 
TBS-T followed by incubation with horseradish peroxidase-labeled secondary 
antibody. Using SuperSignal West Femto Maximum Sensitivity substrate 
(Thermo Scientific), immunoblots were visualized by exposing membranes to x-
ray film. 
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2.4  Flow cytometry 
HeLa cells growing in cultures were washed, trypsinized and harvested in 
PBS and fixed in 70% ethanol overnight at 20oC. After treatment with 1 mg/ml 
RNase A (Sigma) at 4oC for 60 minutes, DNA staining was performed using 
propidium iodide (Invitrogen) in the dark, prior to flow cytometric analysis. 
Analysis was performed on a FACS flow cytometer (Becton Dickinson, USA). For 
each sample, 25,000 events were collected and aggregated cells were gated out. 
The percentage of cells existing within the different phases of the cell cycle was 
determined using CellQuest Pro software. 
 
2.5  RNA isolation and quantitative real-time-PCR  
Total cellular RNA was prepared using TRIzol reagent (Invitrogen) 
according to the instruction manual. Cells were lysed directly in the culture dish. 
Samples were incubated for 5 minutes in TRIzol at room temperature. 
Chloroform 0.2 ml was added for every 1 ml of TRIzol used. Samples were 
shaken vigorously for 15 seconds and incubated at room temperature for 2-3 
minutes. Samples were centrifuged for 15 minutes. at 12,000 x g at 4°C. The 
RNAs were precipitated by mixing with 0.5 ml of isopropanol for each 1 ml of 
TRIzol used. Samples were incubated at room temperature for 10 minutes and 
centrifuged for 10 minutes at 12,000 x g at 4°C. Then pellets were washed with 1 
ml of 75% ethanol and the RNAs were dissolved in RNase free H2O. 
The first strand cDNAs were synthesized used a high capacity cDNA 
reverse transcription kit (AppliedBiosystems) according to the instruction manual. 
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RT-PCR mixtures were prepared by using TaqMan® Gene Expression Master 
Mix (Appliedbiosystems) with a probe specific to human cyclin B1 or AURKA 
(AppliedBiosystems, Hs01582072_m1, NM_003600), and GAPDH 
(AppliedBiosystem, Hs02758991_g1) was used as a control. The RT-PCR 
reaction and analysis were performed using a 7900HT system 
(AplliedBiosystem). 
 
2.6  Cap-binding assay 
For the affinity purification of eukaryotic mRNA cap-binding proteins, 
Sepharose 4B and 7-Methyl GTP-Sepharose 4B were obtained from GE Health 
Sciences. After washing with PBS, 1.5 × 106 cells were lysed in 1 ml of lysis 
buffer (50 mM HEPES at pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM Na3VO4, 25 
mM glycerophosphate, complete mini protease inhibitor cocktail [Roche], and 
0.5% NP-40) and extracts clarified by centrifugation at 10,000 × g for 10 minutes, 
at 4°C. Supernatants pre-cleared with Sepharose 4B 30 μl for 20 minutes were 
next incubated with 7-Methyl GTP-Sepharose 4B 30 μl for 2 hours at 4°C. After 
incubation, the beads were spun down at 2000 rpm for 5 minutes and washed 
three times with lysis buffer, denatured by the addition of 50 μl sample buffer and 
boiled at 100oC for 5 minutes, and the bound proteins were analyzed by SDS-
PAGE and immunoblotting [131]. The protein levels were quantitated by 
phosphoimager software. 
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2.7  Rapid Amplification of cDNA Ends (5' RACE) 
In mammalian cells, there are 6 transcriptional splicing variants of Aurora 
A. In order to know which version existed in HeLa cells in this study, we carried 
out a 5’RACE assay (Invitrogen) according to the manufacturer’s instructions. 
The total RNA was obtained from the kit. First strand cDNA was synthesized 
from total RNA using a gene-specific primer Aurora-A 5’UTR reverse R1, 5’-
CAGTTTTCTTTAGATCGGTCC and M-MLV RT (a derivative of moloney murine 
leukemia virus reverse transcriptase). After the first strand cDNA synthesis, the 
original mRNA template was removed by treatment with the RNase Mix. 
Unincorporated dNTPs, primer AURKA R1, and proteins were separated from 
the cDNA using a S.N.A.P. Column. A homopolymeric tail was then added to the 
3'-end of the cDNA using terminal deoxynucleotidyl transferase and dCTP. Tailed 
cDNAs were then amplified by PCR using a mixture of three primers: a nested 
primer reverse AURKA R2, 5’-GAAAATGCTGGGATTACGGG-3’, which 
annealed 3' to the AURKA R1; and a combination of a complementary 
homopolymer-containing anchor primer and corresponding adapter primer which 
permit amplification from the homopolymeric tail. Following an initial denaturation 
step at 94 °C for 3 minutes, 35 cycles of 30 s at 94 °C, 1 minute at 55 °C, and 1 
minute at 72 °C were run. The final extension step at 72 °C was carried out for 10 
minutes. The 5′-RACE products were then analyzed using electrophoresis on a 2 
% agarose gel. The prominent DNA bands were excised, gel purified and sub-
cloned into pCR 2.1vector (TA Cloning Kit, Invitrogen) and sequenced. The 
 49 
 
transcriptional start site was determined as the first nucleotide that is 3’ to the 
adapter sequence ligated to the 5’of the mRNA transcripts. 
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Figure 2.1  Overview of the 5’ RACE procedure based on a figure from 
Invitrogen (5’ RACE version 2.0)  
 
First strand cDNA is synthesized from total RNA using a gene-specific primer 
AURKA R1. After first strand cDNA synthesis, the original mRNA template is 
removed by treatment with the RNase Mix. The cDNA is purified with a spin 
cartridge. A homopolymeric tail is then added to the 3'-end of the cDNA. PCR 
amplification is conducted with a nested, gene-specific primer R2. Following 
amplification, 5' RACE products can be cloned into the pCR 2.1 vector for 
sequencing (Invitrogen 5’ RACE version 2) 
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2.8  Lentiviral production and transduction for knock down 
Mission shRNAs FZR1/cell division cycle 20 related 1(Cdh1) were 
obtained from Sigma as follows:  
 
 
Table 2.1  FZR1/Cdh1 shRNA sequences. 
 
These shRNAs target different sites of coding region of Cdh1 mRNA.  
 
To produce lenti-viral shRNA, HEK293T cells were plated at 6x105 
cells/well in a 6-well plate. At next day the cells were transfected with 1μg Lenti-
viral constructs containing shRNAs and 4.6 μl lentiviral packaging mix (Sigma) 
with Fugene 6 (Roche) according to the manufacturer’s instructions [132]. At 48 
and 72 hours post transfection, the supernatants containing the virus were 
harvested and centrifuged at 15,000 rpm for 3 minutes. The pellets were 
discarded and the supernatants were stored at -80oC until needed. 
To knock down the endogenous FRZ1 gene, HeLa cells were plated at 
1.5X105 cells/well in a 6-well plate. At next day, the cells were transduced with 
the Lenti-viral shRNAs 0.5 ml and 8 μg/ml polybrene. At 72 hours post 
transduction, the cells were lysed and knockdown level of Cdh1proteins (FZR1 
products) were analyzed by immunoblotting assay.  
Sigma cat # Sequence
TRCN0000010856 NM_016263.x-457s1c1 CCGGCGGCAACGATGTGTCTCCCTACTCGAGTAGGGAGACACATCGTTGCCGTTTTT
TRCN0000231901 NM_016263.2-209s21c1 CCGGGTGAACTTCCACAGGATTAACCTCGAGGTTAATCCTGTGGAAGTTCACTTTTTG
TRCN0000231902 NM_016263.2-405s21c1 CCGGAGAAGGGTCTGTTCACGTATTCTCGAGAATACGTGAACAGACCCTTCTTTTTTG
TRCN0000231903 NM_016263.2-1434s21c1 CCGGTGAGGTTCTGGAACGTCTTTACTCGAGTAAAGACGTTCCAGAACCTCATTTTTG
TRCN0000231904 NM_016263.2-1498s21c1 CCGGCTTCACCAGGATCCGGTAAACCTCGAGGTTTACCGGATCCTGGTGAAGTTTTTG
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2.9  RNAi and transfection 
Commercial pool siRNA duplexes targeting to Rheb were obtained from 
Dharmacon/Thermo Biosciences. HeLa cells were plated at 1.5 x 105 cells/well in 
a 6-well plate and incubated for 24 hours before siRNA transfection. 
Oligofectamine reagent (Invitrogen) was used to transfect siRNA into the cells, 
basically following the recommended procedures by Invitrogen. Typically 50 nM 
siRNA oligos along with 4 μl oligofectamine reagent for HeLa cells were used per 
transfection. Protein lysates were harvested 48 hours after transfection to 
analyze knockdown levels of Cdh1 proteins by immunoblotting as described 
previously.  
 
2.10  Luciferase assay 
The 133-bp of AURKA variant 6 and the 243-bp variant 5 (see the 
sequences below) were synthesized by gene synthesis (GenScript), with Kas I 
and HindIII restriction sites at the 5’and 3’ ends, respectively. Synthesized 
fragments were cloned into TK-Luc vector [133] at corresponding restriction sites. 
The isolated clones were confirmed by sequencing. Plasmid transfections were 
performed using HeLa cells grown to 40% confluence and the FuGENE 6 
transfection reagent (Roche Applied Science). The transfections were carried out 
in triplicates using TK-AURKA variant 5-Luc or TK-AURKA variant 6-Luc 
plasmids, with TK-Luc plasmids serving as an internal control (Promega). 24 
hours post transfection, KU63794 1 μM was added to the cell medium. After 2 
hours mTOR inhibitor treatment, firefly luciferase activity was measured by 
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Envision with value of relative light units. Results are presented as means +/- SD 
that were derived from three independent experiments. Parallel to the luciferase 
assays, the amount of firefly luciferase mRNA in each transfected condition was 
measured by qRT-PCR method. Efficiency of mTOR inhibition by KU63794 was 
examined by immunoblotting assay as described previously.   
 
2.11  Rac1 activity assay 
Transfected HeLa cells were washed twice in ice cold phosphate buffered 
saline (PBS), and lysed in 1 ml of lysis buffer containing 50 mM Tris HCl pH 7.4, 
10% glycerol, 200 mM NaCl, 2.5 mM MgCl2, 1% IGEPAL (Sigma) and protease 
inhibitors 1 mM p-methylsulfonylfluoride (PMSF) and 0.05 trypsin inhibitor 
units/ml of Aprotinin at 4°C for 5 minutes. The cellular extracts were harvested 
and centrifuged at 14,000 rpm for 5 minutes. Eight hundreds μl of the cleared 
lysate were then rocked with 30 μl of GST-PAK-RBD-bound beads for 45 
minutes at 4°C to pull down GTP bound Rac1. The beads were then washed 
three times with the above described buffer. Rac1 was detected by running the 
samples on SDS page gels and immunoblotting with the Rac1 specific antibody 
[134, 135].  
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2.12  Chemotaxis assay 
Following siRNA treatment for 48 hours, U373MG cells were detached 
and loaded in the upper portion of the chamber, allowing cells to move through a 
permeable filter toward 0.1% Fetal Bovine Serum (FBS) present in the lower 
portion of the chamber [136] [137, 138]. After 16 hours, non-migrating cells on 
the upper filter surface were removed with a cotton swab, and migrated cells on 
the bottom of the filter were fixed with 10% neutral buffered formalin for 10 
minutes and stained with crystal violet dye. The mounted filter membranes were 
photographed with a microscope equipped with a camera at 1x100 magnification 
and 5 fields were quantified for each slide. The data presented in this study 
represent three independent experiments  
 
2.13  Statistical analysis 
Data were expressed as mean and standard error of the mean. Statistical 
analysis was performed with a two-tailed unpaired student t-test. A P-value of < 
0.05 was considered to be statistically significant. All calculations were performed 
on the means of triplicate measurements of at least three independent 
experiments. 
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CHAPTER 3  RESULTS 
 
Rheb/mTOR Pathway Regulates Cell Migration 
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3.1  Rheb regulates ribosomal S6 activation in U373 glioblastoma tumor 
cells. 
Rheb is highly expressed in the brain; S6 phosphorylation level is elevated 
in PTEN-deficient glioblastoma brain tumor samples (Lawrence Quilliam, et al. 
unpublished), so I anticipated that the PI3K/Rheb/mTOR pathway would be 
functioning in U373MG, a PTEN-deficient human glioblastoma cell line, and if so, 
blocking Rheb expression would block the important PI3K/mTOR signaling to 
activate S6. To test this notion, I first determined whether the Rheb protein is 
expressed in cultured U373MG cells and we then examined if knocking down 
Rheb expression can reduce phosphorylation of ribosomal protein S6 
downstream of mTOR. As expected, the level of Rheb protein is readily detected 
in U373MG cells. Notably, suppressing Rheb with siRNA reduced the S6 
phosphorylation level (Figure 3.1), suggesting that Rheb lies upstream of the 
mTOR pathway in U373MG cells.  
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Figure 3.1  Knocking down Rheb reduces ribosomal S6 phosphorylation 
 
U373MG were transfected with 50 nM of short interfering (si) RNAs, either non-
targeting 2 (control) or Rheb. After 48 hours, the cells were lysed and equal 
amounts of the proteins were analyzed by immunoblotting using specific 
antibodies to Rheb and phosphorylation of S235/236 residues of ribosomal S6 
protein, and total S6 protein level served as a loading control.  
A. siRNA pool is shown in A and three unique Rheb siRNAs to Rheb in B. 
siCTRL was a control, which represents a sequence not present in human or 
mouse genomes. A siRNA to the mTORC1 component, Raptor, was used as a 
positive control. 
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3.2  Knocking down Rheb induces F-actin reorganization and elevates 
Rac1-GTP levels  
Interestingly, suppressing Rheb expression in the U373MG glioblastoma 
cell line also was found to change cell morphology and cytoskeletal organization. 
F-actin staining with fluorescently-tagged phalloidin showed actin polymerization 
at the leading edge of the cells in fan assemblies, or lamellipodia following 
depletion of Rheb expression (Figure.3.2A). Since lamellipodia are induced by 
the Rac1 GTPase, I next asked if Rac1 is activated after knocking down Rheb. 
Pulling down Rac1 with GST-RBD-PAK (a GST fusion protein containing the 
Rac1-GTP-binding domain of p21 Rac1/Cdc42-activated protein kinase, 
immobilized on glutathione agarose beads) was conducted. Indeed, the elevated 
GTP-bound Rac1 was found in cells following Rheb knock down, compared to 
cells treated with control siRNA (Figure. 3.2B.(i)). To overcome potential siRNA 
off-target effects, we employed three Rheb siRNAs targeting different regions of 
the Rheb mRNA. Consistently, depletion of Rheb expression with these siRNAs 
elevates Rac1 GTP levels (Figure.3.2B.(ii)), supporting our hypothesis that Rheb 
mediates Rac1 activation. 
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Figure 3.2  Knocking down Rheb expression in U373MG cells induces 
changes in the actin organization and Rac1 activation. 
 
A. F-actin distribution. U373MG cells were transfected with 50 nM siRNA to Rheb 
and to control for 48 hours, followed by fixation and stained with fluorescently-
tagged phalloidin. 
 
B.(i). A protocol of Rac1-GTP pull-down assay; To measure Rac1-GTP level, 
three hundreds ug of cellular extract, from U373 MG cells previously transfected 
with siRNAs for 48 hours, were incubated with 20 μl of purified GST-PBD PAK1 
at 4○C for 1 hour. The reaction mixtures were precipitated with glutathione-
conjugated Sepharose beads, the amounts of GTP-bound Rac1 were determined 
by immunoblotting. 
 
B.(ii). Three siRNAs to Rheb regulate Rac1-GTP levels. Rac1 siRNA was used 
as a negative control. 
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3.3  Suppression of Rheb expression induces cell migration  
I next examined the biological relevance of Rheb-mediated Rac activation. 
chemotaxis assays were conducted to determine directional movement of cells 
depleted of Rheb toward chemoattractant, fetal bovine serum, as demonstrated 
in Figure 3.3A and 3.3B. Loss of Rheb accelerated U373MG cell migration 
across a permeable filter toward 0.1% FBS by ~2 fold, using a single Rheb 
siRNA as shown in Figure 3.3C; similar results were observed in cells treated 
with three unique Rheb siRNA s, compared to siRNA control, as shown in Figure 
3.3D.  
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Figure 3.3  Suppression of Rheb affects cell migration. 
 
A. Protocol of chemotaxis assay. 
 
B. Following siRNA treatment for 48 hours, cells were loaded in the upper portion 
of the chamber, allowing cells to move through a permeable (8 μm pore size) 
filter toward 0.1% FBS present in the lower portion of the chamber. After 16 
hours, cells that had migrated through the filter were fixed with 10% neutral 
buffered formalin, then stained with crystal violet dye and visualized by 
microscopy. 
 
C. The bar graph shows averaged migration data from four experiments each 
using a single siRNA to Rheb. A student test program showed a statistical 
difference between siRNA Rheb and siRNA control, of p <0.05. 
 
D. Shown the rate of cell migration using three siRNA to Rheb, compared with 
control siRNA. Deletion of Raptor, a key mTORC1 component, served as a 
control.   
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3.4  Rheb-mediated S6 phosphorylation negatively regulates PDGF 
receptor expression  
I next searched for the underlying mechanism of Rheb-mediated 
migration. Recently, it was reported that although the platelet-derived growth 
factor receptor (PDGFR) is an activator of PI3K but the receptor transcription is 
negatively regulated by mTORC1 [20], resulting in decreased receptor 
expression (Figure 3.4A). Since Rheb is upstream of mTOR in the PI3K pathway, 
we asked whether Rheb also affects PDGFR expression. We found that 
depleting Rheb mRNA increased PDGFR alpha expression in U373MG cells. 
Similar results were observed with two additional Rheb siRNAs. In addition, 
suppression of Raptor also elevated PDGFR expression, shown in Figure 3.4B. 
This result provided evidence that a negative feedback exists between mTOR 
signaling and PDGFR expression in U373MG.  
  
 63 
 
 
Figure 3.4  Knocking down Rheb increases PDGFR expression and PDFGR 
inhibitor, Gleevec, reduces Rheb-mediated migration. 
 
A, A reported negative feedback loop between mTOR and PDGFR [20]. 
 
B. Knocking down of Rheb increases PDGFR expression. U373MG cells were 
transfected with 50 nM Rheb siRNAs and control siRNA. Forty eight hours 
thereafter, the cells were harvested. Aliquots of cell lysates containing equal 
amounts (20 ug) of proteins were analyzed by immunoblotting assay using anti-
PDGFRα specific antibody, and ß-actin as a loading control. 
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3.5  PDGFR inhibitor, Gleevec, reduces Rheb-induced migration 
PDGFR expression potentiates cell migration via PI3K/Rac pathway (36). 
To investigate whether Rheb-mediated PDGFR expression affects cell motility, I 
utilized Gleevec, a small molecule tyrosine kinase inhibitor to PDGFR, c-kit and 
Abl (37-38), and monitored the migration ability of cells following Rheb knock 
down. First, I determined Gleevec IC50 is ~10 μM (data not shown) to inhibit 
ERK phosphorylation, a read-out for PDGFR activation. Then, we conducted a 
migration assay using a range of doses of Gleevec. As expected, Rheb-induced 
migration was significantly repressed in the presence, compared to the absence, 
of Gleevec in a dose-dependent manner, demonstrated in Figure 3.5. 
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Figure 3.5  Gleevec, a PDGFR inhibitor, reduces Rheb-induced migration. 
 
Following siRNA treatment for 48 hours, cells were pre-treated with Gleevec at 
5,10 and 20 μM for 2 hours then cells were loaded in the upper portion of the 
chamber, allowing cells to move through a permeable (8 μm pore size) filter 
toward 0.1% FBS present in the lower portion of the chamber. After 16 hours, 
cells that had migrated through the filter were fixed with 10% neutral buffered 
formalin, then stained with crystal violet dye and visualized by microscopy. The 
bar graph shows averaged migration data from three experiments  
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3.6  Summary 
 
 
Figure 3.6  Model of Rheb/mTOR/PDGFR/Rac pathway in cell migration. 
 
Rheb/mTORC1 signaling suppresses PDGFRα protein expression, which in turn 
diminishes Rac1-mediated actin polymerization and decreases cell migration.  
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3.7  Discussion 
Cell migration is an important step for cancer metastasis; however the 
roles of Rheb1/mTORC1 in cell migration are not fully understood. There are 
controversial documents for Rheb’s role in migration. Rheb increasing migration 
was reported in neuronal cells in newborn mice [139, 140]. Whereas others 
previously found that suppression of mTORC1 signaling inhibits tumor growth but 
does not prevent cancer progression in a thyroid cancer model [141]. It may be 
due to the different genetic backgrounds of the tested cell lines. Our lab was 
interested in a potential role of Rheb, in glioblastoma thus U373MG, a PTEN-
deficient human glioblastoma cell line, was selected in this study. We found that 
knocking down Rheb induces F-actin reorganization and Rac1 activation, 
consequently enhancing cell migration in the U373MG cells. Furthermore, 
abrogation of Raptor, a Rheb downstream mTORC1 component had similar 
results - increasing migration, confirming that Rheb/mTOR decreases the 
migration of glioma cells.  
I found that the mechanism underlying this action is that Rheb knockdown 
induces a negative feedback loop that activates PDGFR expression and Rac1 
activation. In addition, depletion of Raptor behaves similarly. Zhang, et al. (2007) 
reported that in TSC1/2-/- (upstream negative regulator of Rheb) cells, Akt 
activation is remarkably reduced in response to serum and PDGF stimulation, 
along with a reduction in cell ruffling. PDGFRα expression is tremendously 
decreased in this cell line [20]. This illustrates an mTOR negative feedback loop 
on PDGFR that is consistent with our findings. mTOR exists in two different 
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complexes, mTORC1 and mTORC2. It is possible that there is crosstalk between 
these two complexes. For example, inhibition of mTORC1 by DEPTOR 
overexpression activated mTORC2 by releasing mTORC1’s negative feedback 
loop on mTORC2 [142]. There are also reports that inhibiting mTORC1 with 
rapamycin lead to mTORC2 activation in multiple cancer cell lines [23]. Thus, it 
would be interesting in future to measure mTORC2 substrate Akt Ser473 
phosphorylation in this study. 
PDGF is an activator of Rac1 and stimulates Rac1-dependent migration of 
fibroblasts and vascular smooth cells [143, 144]. We found that treating Rheb-
depleted cells with PDGFR inhibitor Gleevec reverses Rheb-depletion-induced 
cell migration, suggesting that PDGFR is in the Rheb/mTOR/Rac1 pathway. 
Since this small molecular may also target other proteins in the cells, it would be 
interesting to have additional approach such as knockdown of PDGFR to further 
confirm the mechanism of this action. 
In term of clinical implication, my works suggest that when treating cancer 
with Rheb/mTOR inhibitors, optimal chemotherapy may be achieved by addition 
of a migration inhibitor, such as PDGFR inhibitor, to reduce both cell growth and 
cell migration/metastasis.  
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CHAPTER 4  RESULTS 
 
mTOR REGULATES AURORA A VIA ENHANCING PROTEIN STABILITY 
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4.1  mTORC1 is active during G2/mitosis in mammalian cells. 
 The function of mTOR in the G1 phase of the cell cycle has been 
extensively studied, while its role in G2 and mitosis is much less understood. To 
explore the role of mTORC1 signaling on mitosis, I first examined whether there 
was a correlation between mTOR activity and G2/M phase progression. HeLa, 
human cervical cancer cells, were utilized. These cells were selected because 
(1) they were derived from a cancer, (2) they are a commonly used human cell 
line in many research fields, such as infectious disease [145], AIDS [146],and 
cancer [147]. (3) Most importantly, HeLa cells can be effectively synchronized in 
S phase entry by removal of thymidine. Release of the cells from thymidine 
blockade enabled us to follow gene expression and other events when the cells 
subsequently pass through the cell cycle. As shown in Figure 4.2.1, HeLa cells 
were accumulated in the G1/S phase by double thymidine blockage/release, 
measured by FACS analysis. At 3.5, 4 and 5 hours post release, cells entered 
the early, middle and late S phases, respectively, and at 8 hours were in the G2 
phase, shown by 4N DNA and cyclin B1 reaching its peak expression. At 10 
hours post release, cells entered the mitotic phase, demonstrated by the mitotic 
marker histone H3 phosphorylation peak. To monitor mTOR activity, 
phosphorylation of its downstream substrates, S6K1 and 4E-BP1, was measured 
at various time points of the cell cycle by quantitative immunoblotting analysis. As 
shown in Figure 4.1, when cells entered the S phase, phosphorylation of S6K1 
started to increase and reached its peak during the G2/M phases; 4E-BP1 
phosphorylation, including theT37/46 and S65 sites, was also elevated in the 
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G2/M phases, notably S65 was remarkably increased. These results indicated 
that mTOR activity preceded or coincided with the G2/M phases and suggest that 
mTOR may be involved in regulation of mitosis during the cell cycle. 
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Figure 4.1  mTOR signaling is higher in G2/M phases  
 
A. Schematic of double thymidine block/release assay. 
 
B. HeLa cells were synchronized with double thymidine block/release, as 
indicated in Methods and Materials. At 4 hours cells reached S phase, 8 hours 
G2, and 10 hours mitosis. The cellular proteins were collected and the 
expression levels and phosphorylation status of mTOR substrates, S6K1 and 4E-
BP1, were determined by immunoblotting assay using antibodies specific against 
phospho- and total proteins.  
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4.2  Inhibiting mTOR signaling suppresses mitotic progression  
To address whether mTOR affects mitotic progression, I utilized the well-
characterized mTOR inhibitor, rapamycin to inhibit mTOR activity. Subsequently, 
we monitored mTOR effects on cell cycle progression by immunoblotting for the 
mitotic marker phospho-Histone H3 Ser10 (S10) and monitored cell population 
change by flow cytometry. Rapamycin was administered at 4 hours or 5 hours 
post thymidine release based on the flow cytometry (Figure.4.2), to avoid drug 
interference with G1- or S-phase progression. The results showed that 
rapamycin treatment abolished S6K1 T389 phosphorylation. Interestingly, 4N 
DNA containing cells were reduced by 10% and mitotic maker Histone H3 S10 
was also decreased in the M phase, compared to vehicle control. These findings 
support the above notion that mTOR regulates the mitosis phase of the cell 
cycle.  
.  
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Figure 4.2  Inhibiting mTOR signaling suppresses mitotic progression. 
 
A. Flow cytometry shows that at 3.5 and 5 hours post release from thymidine 
block, cells were in the course of the S phase. It suggests that administering 
mTOR inhibitor at 4 or 5 hours post release should not interfere with S phase 
progression. 
 
B. HeLa cells were treated with rapamycin at 4 and 5 hours post release from 
thymidine, and at 10 hours the cell populations were analyzed by FACS. The 
data are representative of two experiments. 
 
C. Cellular lysates were collected from duplicated samples and mTOR substrate 
S6K1 and mitotic marker Histone H3 S10 were examined by immunoblotting 
assay using antibodies specific against phosphor- and total proteins.  
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4.3  Comparison of using double thymidine to RO-3306 in synchronizing 
cells 
Use of double thymidine block (via inhibition of DNA synthesis) to 
synchronize cells is very time-consuming [148, 149]. It takes about 40 hours to 
synchronize cells at G1/S phase, including a 1st16 hours thymidine-treatment to 
block; wash/release cells into the cell cycle for 8 hours; then a 2nd thymidine 
treatment for 16 hours, followed by wash and release to allow cells to enter the 
cell cycle. In addition, it takes about an additional 8 hours from the G1/S to G2/M 
phases, in which we are interested, see Figure 4.2. Thus, when reaching to 
G2/M, cell populations may already be regaining an asynchronous state [149]. 
Recently, Vassilev, et al proposed a simple, fast method to synchronize 
cells by inhibition of Cdk1activity, based on well-known, essential role of 
Cdk1/cyclinB in G2/M transition [148] In this method, a selective, reversible Cdk1 
inhibitor, RO-3306, is used for treating cells to block proliferating cells at the 
G2/M phase transition site. After washing off the drug, the cells are released from 
the inhibitory effect and rapidly enter M phase. In this one single‑step procedure 
for about 20 hours, one can generate highly synchronous populations of G2/M 
cells which are useful for both cytological and biochemical studies [95, 149]. A 
comparison of thymidine block to RO-3306 in synchronizing cells is showed in 
Figure 4.3. Therefore, I utilized RO-3306 in my subsequent studies for 
synchronization of HeLa cells.  
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Figure 4.3  Comparison of using double thymidine to RO-3306 in 
synchronizing cells 
 
A. A double thymidine block/release approach takes multiple steps over a 48 
hours time-period to reach a synchronized G2/M transition. 
 
B. Treatment with Cdk1 inhibitor RO-3306 only takes a single 20 hours treatment 
to block cells at G2/M border. 
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4.4  Inhibiting mTOR signaling suppresses mitotic progression, continued 
As see in Figure 4.4, 72 % of cells had 4N DNA contents, which were 
analyzed by fluorescence-activated cell sorting (FACS). The phosphorylation of 
mitotic maker Histone H3 S10 was faint when analyzed by immunoblotting, 
indicating that cells were in the G2 phase. 
 
Figure 4.4  Inhibiting mTOR signaling suppresses mitotic progression.  
HeLa cells were synchronized with Cdk1 inhibitor RO-3306 for 19 hours. 
 
A. The synchronization efficiency was determined by FACS as described 
previously. 
 
B. The cells were then treated with mTOR inhibitor rapamycin 100 nM for 2 
hours, followed by washing and releasing cells into the cell cycle. One set of the 
samples were continued to treat with mTOR inhibitor by adding rapamycin 
immediately after release and another set with vehicle DMSO. The cellular 
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extracts were harvested at indicated times, and mitotic marker Histone H3 S10 
and mTORC1 substrate S6K1 were examined by immunoblotting assays. 
 
C. Diagram showing quantitation of Histone H3 S10 phosphorylation from four 
experiments. 
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4.5  Aurora A mitotic kinase is most obviously affected by mTOR  
Mitosis progression is tightly regulated by multiple protein kinases, such 
as ataxia telangiectasia mutated (ATM), check 1 (Chk1), Aurora A, and polo-like 
kinase 1 (Plk1), and cyclin-dependent kinase 1 (Cdk1) to ensure DNA integrity 
and chromosome being aligned properly before DNA segregation and cell 
division. Based on these well-documented facts, I asked which mitotic kinase is 
regulated by mTOR signaling. HeLa cells were treated with mTOR inhibitor 
rapamycin for 2 hours and immunoblotting assays were shown in Figure 4.5.1, 
Aurora A protein level and its phosphorylation on T288, an active site on its T 
loop, were obviously down regulated, while .ATM, Chk1, and Plk1 and Cdk1 
proteins remained unchanged. Interestingly, cells treated with the mTOR inhibitor 
displays monopolar chromosomes, which is one of characters of Aurora A 
defects due to centrosome duplication and spindle assembly (Figure 4.5.2). 
These results suggest that Aurora A might be a target for mTOR regulation. 
Thus, I selected Aurora A in this study to explore how mTOR regulates Aurora A 
mitotic protein.  
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Figure 4.5.1  Aurora A is most obviously affected by mTOR inhibition. 
 
A. Mitotic kinase signaling from ATM, to Chk1; Aurora A, Plk1; and Cdk1. 
 
B. HeLa cells were treated with mTOR inhibitor rapamycin 100 nM for 2 hours. 
The cellular lysates were collected and equal proteins were subject to SDS-
PAGE. The kinases described above were examined by immunoblotting assays 
using specific antibodies against ATM, Chk1, Aurora A, Plk1 and Cdk1 proteins. 
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Figure 4.5.2  Misalignment of chromosomes and monopolar chromosomes 
were observed in HeLa cells. 
 
HeLa cells were treated with mTOR inhibitor KU63794 1μM for 24 hours, then 
fixed with 4% paraformaldehyde. The chromosomes were stained with DAPI and 
visualized by fluorescence microscopy.  
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4.6  Blocking mTOR activity reduces Aurora A protein levels   
Aurora A is a key Ser/Thr kinase protein that plays important roles not only 
in mitosis of the cell cycle, but also in tumorigenesis. Thus Aurora A became a 
prime candidate for further testing. In this study, two types of synchronization 
approaches: double thymidine blockage method and Cdk1 inhibitor RO-3306 
blockage/release were utilized. At both experiments, mTOR inhibitors reduced 
Aurora A protein levels shown in Figure 4.6.1 and 4.6.2. These results suggest 
that mTOR regulates Aurora A expression, at least at the protein level. Further, 
phosphorylation of histone H3 S10, which is spatio-temporal regulated by Aurora 
A kinase [150], was diminished after rapamycin and Torin1 treatment during 
mitotic progression. These findings support the hypothesis that mTOR regulates 
mitotic Aurora A during the cell cycle.  
Another phenomenon observed is that rapamycin (an allosteric inhibitor) 
and Torin1 (a kinase catalytic inhibitor) have different effectiveness of inhibiting 
phosphorylation of S6K1 vs. 4E-BP1, the two substrates of mTORC1, see Figure 
4.6.1, both mTOR inhibitors abolished phosphorylation of the S6K1, and Torin1 
also completely suppressed phosphorylation of 4E-BP1, including its sites at 
T37/46, S65, and T70 but rapamycin only partially affected phosphorylation 
status of 4B-BP1. These data indicate that the allosteric effect is not sufficient to 
completely inhibit mTORC1 activity, while the kinase active site inhibitor does. 
This agreed with others reports [57, 60, 151]. Based on these observations,  
Torin1 and another ATP-competitive inhibitor, KU63794 were used in my 
subsequent experiments. 
 83 
 
A. 
 
 
Figure 4.6.1  Blocking mTOR activity reduces Aurora A protein level. 
 
HeLa cells were synchronized by double thymidine blockage/release. At 6 hours 
post release, mTOR kinase catalytic inhibitor Torin1 250 nM or mTOR allosteric 
inhibitor rapamycin 100 nM were administered. Cellular lysates were collected at 
the indicated times post release and equal amounts of proteins were subject to 
immunoblotting assay with specific antibodies as indicated. 
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Figure 4.6.2 Blocking mTOR activity reduces Aurora-A protein level, 
continued. 
 
B. Diagram indicating mTOR protein structure, kinase domain and FKBP12 
binding domain 
 
C. Diagram showing mTORC1 has two well-known substrates, S6K1 and 4E-
BP1. Rapamycin binds FKBP12, then this complex bind the FKBP12-Rapamycin 
E. 
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Binding (FRB) domain, an allosteric site of mTOR, inhibiting indirectly mTORC1 
activity. Torin1, KU37694, and PP242 directly bind and repress mTOR kinase 
activities. They are ATP-competitive mTOR kinase inhibitors that block all 
mTORC1 and C2 activity while rapamycin preferentially inhibits mTORC1-
mediated phosphorylation of S6K [151]. 
 
D. HeLa cells were incubated with RO-3306 5uM for 19 hours then pre-treated 
with rapamycin, Torin1, KU63794, or PP242 for 1 hour (still in presence of RO-
3306). The cells then were washed with warm medium and released to the fresh 
medium, followed by immediately treating with indicated inhibitors or DMSO. 
Cells were lysed at 2 hours after release. Equal amount of cellular proteins were 
subject to immunoblotting assays using specific antibodies against S6K1, 4E-
BP1, Aurora A, and CDK1proteins, GAPDH was used as a loading control. 
 
E. Quantitation of Aurora A proteins. Results represent the means ± the standard 
errors from three experiments. * indicates p < 0.05 compared to vehicle control 
using a two-tailed, paired Student's t test.  
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4.7  Potential mechanisms for mTOR regulation of Aurora A 
It is known that mTOR controls certain genes of transcription [20] or 
translation [79], and/ or protein stability [79]. However, it is unknown whether 
mTOR regulates Aurora A through one or more these ways, I attempted to 
address these questions one by one as follows.  
 
 
Figure 4.7  Putative approaches for mTOR regulation of Aurora A. 
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4.8  mTOR does not affect Aurora A transcription 
The detected Aurora A protein level change could have been the result of 
altered gene transcription, transcript stability, translation and/or protein stability. 
Therefore, I examined whether mTOR mediates AURKA transcript levels. Since 
AURKA transcription mostly occurs in the G2 phase of the cell cycle [152], HeLa 
cells were blocked at the G2/M border utilizing Cdk1 reversible inhibitor RO-3306 
[148], followed by treatment with mTOR allosteric inhibitor rapamycin and active-
site direct inhibitors TORin1, KU63794 [61], and PP242. TaqMan quantitative 
PCRs were carried out to analyze the mRNA levels of AURKA using AURKA 
specific primer/probe. As shown in Figure 4.8, the mRNA messages remained 
unchanged in rapamycin treated cells as well as Torin1, KU63794, and PP242 
treated samples, indicating that mTOR has minimal effect on the steady-state 
AURKA transcription levels.  
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Figure 4.8  mTOR does not affect Aurora A transcription 
 
HeLa cells were incubated with RO-3306 5μM for 15 hours, then treated with 
mTOR inhibitors rapamycin 100nM, Torin1 250nM, KU63794 1μM, and PP242 
750nM for additional 4 hours. For a mitotic control, cells were treated with 
Nocodazole 100nM for 19 hours. Total RNAs were isolated and quantitative 
PCRs were conducted using specific primer/probe against AURKA and GAPDH 
mRNAs. Nocodazole is an anti-microtubule agent, which interferes with the 
polymerization of microtubules and dynamic microtubule network to form the 
mitotic spindle. Thus Nocodazoleblocks cells at mitosis, served as a control. The 
data represent three independent experiments.  
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4.9  Suppression of mTOR affects translational apparatus assembly in 
HeLa cells 
I next asked whether mTOR regulates Aurora-A at the translation level. To 
examine this possibility, we first performed a cap-binding experiment to see if 
mTOR inhibitors affect translation apparatus assembly in this cell line. I treated 
cells with various mTOR inhibitors for 2 hours to block canonical mTORC1-
dependent events and capture the cellular 5’ cap complex with m7GTP-
Sepharose beads that mimic the mRNA 5’ cap structure. The results (Figure 4.9) 
showed that 4E-BP1 was largely retained on m7GTP-Sepharose following 
treatment with mTOR inhibitors rapamycin, Torin1, KU63794 or PP242, 
coincident with reduced association of eIF-4G1 with eIF4E. These effects were 
more obviously seen using inhibitors targeting the kinase domain versus 
rapamycin, suggesting that potential mRNA translational regulation may primarily 
be regulated by 4E-BP1, in agreement with other investigators [69, 153]. 
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Figure 4.9  4E-BP1 competes off eIF-4G1 binding to eIF4E with mTOR inhibitors. 
A. Model of translational apparatus assembly. In the absence of nutrients or GF, 
non-phosphorylated 4E-BP1 binds tightly to the translation initiation factor eIF4E, 
preventing it from binding to 5'-capped mRNAs and recruiting them to the 
ribosomal initiation complex. In the presence of nutrients or GF, mTOR 
phosphorylates 4E-BP1, resulting in liberation of eIF4E and its recruitment into 
the translation-initiation-factor complex (eIF4F), which includes eIF4A and eIF4G, 
so promoting mRNA translation. The figure was obtained from [154]. 
 
B. Inhibition of mTOR affected translational apparatus assembly in HeLa cells. 
Cells treated with the indicated mTOR inhibitors for 2 hours were subject to 
m7GTP cap binding assay. Briefly, cell extracts were incubated with m7GTP-
Sepharose beads (that mimic the mRNA 5’ cap structure), then washed and 
bound proteins resolved by SDS-PAGE. 4E-BP1, eIF-4G, and eIF4E proteins 
were examined using specific antibodies in immunoblotting assays. 
  
A. 
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4.10  mTOR facilitates Aurora A translation via short transcriptional 
splicing 
Based on the above data for the global effect of mTOR-mediated 
translation, I next examined whether mTOR mediates specific gene AURKA 
mRNA translation. Since there are 6 splice variants for the AURKA in mammalian 
cells, each having a different 5’UTR (Figure 1.6) but sharing a common coding 
region, I first asked which transcript variant(s) exist in HeLa cells, the cell line that 
has been used throughout this study. To address this question, I carried out a 5’ 
RACE assay to isolate 5' ends of AURKA from HeLa (Figure 4.10.1). Sequencing 
revealed that among nine isolated clones, eight were variant 5 isoform of AURKA 
5’ UTR and one was an unrelated sequence. The transcriptional start site was 
determined as the first nucleotide that is 3’ to the adapter sequence ligated to the 
5’of the mRNA transcripts. Additionally, using specific primers for each 
alternatively splicing variant of AURKA un-translated region, the variant 6 of the 
gene was also found in 5’ RACE mixture extracted from the HeLa cells, albeit at 
much lower abundance than variant 5, in Figure 4.10.2. Thus, two isoforms of 5’ 
leaders, variant 5 and 6, were identified in the HeLa cells. Variant 5 is 243 
nucleotides in length, containing the exons I and II, whereas the latter is 133 
nucleotides, containing only exon I. Interestingly, AURKA variant 5, but not 6, has 
a single upstream ORF (uORF) encoding 39 residues. This uORF is out of frame 
with the initiating ATG in the 5’ UTR AURKA and terminates after 39 codons at a 
TGA within the coding region of AURKA (Figure 4.10.3). I anticipated that this 
uORF might potentially force ribosomes to prematurely initiate translation at the 
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uORF and pass the true initiating ATG and drop off without translating Aurora A 
as has previously been described for CHOP [133]. These features might confer 
translational regulation of Aurora A by the mTOR/eIF4E pathway. To address 
whether the 5’UTR sequence of the AURKA transcript plays a role in its 
translation control, I used a pTK-Aurora A-Luc reporter, which contained a cDNA 
segment encoding the human AURKA 5’UTR segments of variant 5 or 6 fused to 
firefly luciferase [133] downstream of the minimal TK promoter in PGL3 plasmid. 
These constructs were transfected into HeLa cells, and luciferase activity 
measured following treatment of cells with mTOR inhibitor KU63794 for 2 hours. 
Surprisingly, the Luc activity derived from the variant 5 reporter plasmid was not 
significantly affected by mTOR inhibition with KU63794. In contrast, the 
luciferase activity derived from the shorter variant 6-containing reporter was 
decreased 4 folds upon mTOR inhibition (Figure 4.10.4). These findings 
suggested that a short rather than a long, structurally complex 5’UTR might be 
most responsive to mTOR regulation. This contradicts earlier studies [95] but is 
consistent with a recent observation by Thoreen et al. who found that short 5’-
primidine-rich sequences were most responsive to inhibition by Torin1 [69]. This 
will be discussed in detail later. 
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Figure 4.10.1 Alternatively spliced AURKA variant 5 found in HeLa cells. 
 
Cloning of 5’UTR AUKRA from HeLa extract using 5’ rapid amplification of cDNA 
ends (5’RACE) 
 
A. For cloning specific 5’ UTR in HeLa, 5’ primer containing an adaptor sequence 
to capture 5’ cap mRNA; 3’ primer covering 5’ end of Aurora A coding region were 
used for RT-PCR and resulting fragments were inserted into a TA cloning vector 
for sequencing. 
 
B. Sequencing revealed that among nine clones, eight were variant 5 isoform of 
AURKA, and one sequence was non-specific. The transcriptional start site was 
determined as the first nucleotide that is 3’ to the adapter sequence ligated to the 
5’of the mRNA transcripts. 
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                        B. 
 
Figure 4.10.2  Aurora A transcript splicing variant 6 exists in HeLa cells. 
 
A. PCR showing amplification of variants 5 and 6 (albeit faintly) in HeLa. Six 
reverse primers, corresponding to six distinguishing variants and F1 forward 
primer (see APPENDIX 1), which is located in the adjacent translation start site, 
were used in this experiment. The PCR products were separated in a 4% 
agarose and visualized by staining of ethidium bromide. 
 
B.SYBR, a cyanine dye that binds to DNA, was used for quantification of the 
variants # 3, #5 and #6. The primers for SYBR were identical for the PCR 
described above. 
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Figure 4.10.3  Aurora A variant 5, but not 6, has a single upstream ORF 
 
A. Alternative splicing variant 5. A uORF in variant 5 is out of frame with the 
initiating ATG in the 5’ UTR Aurora A and terminates after 39 codons at a TGA 
within the coding region of Aurora A. AURKA coding sequence is shown in red. 
The portion of the uORF prior to the true ATG, along with the uORF stop codon is 
shown in blue. Cartoon is not drawn to scale. 
 
B. Alternative splicing variant 6. This variant contains only a short 5’UTR with no 
uORF. 
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Figure 4.10.4  Short 5’ UTR is sensitive to mTOR inhibition. 
 
A. Constructs of Aurora A variant 5 (or 6)-Luc reporters. The Variant 5 contains 
exon I and II while the Variant 6 only exon I. A stop codon inframe with the uORF 
but out of frame with luciferase was naturally present within the luciferase 
sequence. 
 
B. Luciferase assays were performed in HeLa cells that had been transfected 
with the illustrated constructs for 24 hours, followed by treatment with mTOR 
inhibitor KU63794 for 2 hours. Results represent the means ± the standard errors 
from three experiments. * indicates p < 0.01 compared to vehicle control using a 
two-tailed, paired Student's t test. 
 
C. The levels of Luciferase mRNAs in duplicated samples were measured by RT-
PCR using primer/probe that specifically recognized luciferase mRNA, and 
normalized to cellular GAPDH mRNA. 
 
D. The phosphorylation levels of mTOR substrate 4E-BP1 T37/46 at indicated 
time were examined by immunoblotting assays, using antibodies specific against 
4E-BP1 and its T37/46. GAPDH protein was used as a loading control. 
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Thus, my data is agreement with the Thoreen/Sabatini’s results [69] than 
the EGFR/exon2 study. That is, a 5’-primidine-rich sequence rather than a 
complex 5’UTR is more responsive to mTOR activity. 
 
4.11  Blocking mTOR accelerates Aurora A protein destruction 
The above findings suggest minimal regulation of mRNA 
transcription/stability and only a minor AURKA transcript is responsive to mTOR 
inhibition. Besides regulating transcription and translation, mTOR reportedly can 
maintain the stability of proteins such as cyclin D [79]. If mTOR maintains Aurora 
A protein stability, inhibiting mTOR would accelerate Aurora A destruction. HeLa 
cells were pre-treated with protein synthesis inhibitor cycloheximide (CHX) 50 
ug/ml [155] for 30 minutes before being exposed to mTOR inhibitor KU63794 for 
4 hours. Cells were harvested at different times after KU63794 treatment (t=0) 
and protein levels were analyzed by quantitative immunoblotting assays. As seen 
in Figure 4.11, Aurora A was rapidly degraded in the presence of CHX. This 
occurred much more rapidly in cells co-treated with mTOR inhibitor KU63794. 
Within 30 minutes, the total amount of Aurora A started to decrease in the 
mTOR-inhibited cells. For control cells, it similar as reported previously [99]. This 
suggests that mTOR might prevent Aurora A degradation.  
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                                                               Min. 
Figure 4.11  Blocking mTOR accelerates Aurora A protein destruction.  
A. HeLa cells were pre-treated with protein synthesis inhibitor CHX, 50 μg/ml for 
30 minutes,before being exposed to mTOR inhibitor KU63794 1 μM or vehicle 
DMSO up to 4 hours. Cell lysates were harvested at indicated time points after 
KU63794 treatment (t=0) and equal amounts of the proteins were then subjected 
to SDS-PAGE, and Aurora A, S6K1 protein and its T389 phosphorylation were 
measured by immunoblotting assays.  
 
B. Diagram showing quantitation of Aurora A proteins from three independent 
experiments in a semi-log plot. 
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4.12  Inhibition of proteasome activity prevents mTOR-mediated Aurora A 
destruction  
It is documented that APC induces Aurora A protein turn over, by 
promoting ubiquitination and subsequently degradation by the 26S proteasome in 
later M and G1 phases of the cell cycle [99]. This process is regulated by mTOR 
signaling remains to be ascertained. To address this issue, I used a well-known 
proteasome inhibitor MG132 [156-158], to block protein degradation and used 
KU63794 to block mTOR signaling to see if mTOR affects proteasome-mediated 
Aurora A degradation. The cells were pre-treated with MG132 for 30 minutes 
then exposed to mTOR inhibitor KU63794. Three hours post MG132 treatment 
(two and half hours post KU63794) lysates were subject to immunoblotting 
assays (Figure 4.12). The results showed that (1) inhibiting proteasome activity 
accumulated Aurora A proteins as previously reported [99]. (2) Suppression of 
mTOR activity decreased level of the Aurora A, consistent with my previous data. 
(3) Pre-treated with MG132 prevented Aurora A destruction from KU63794 
treatment, shown in Figure 4.10, indicating mTOR regulates Aurora A protein 
stability via a proteasome-mediated pathway. 
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Figure 4.12  Inhibition of proteasome activity prevents mTOR-mediated  
Aurora A destruction.  
 
A. HeLa cells were pre-treated with proteasome inhibitor MG132 3 μM for 30 
minutes before being exposed to mTOR inhibitor KU63794 or vehicle DMSO for 
additional 2.5 hours. Cell lysates were harvested and equal amounts of the 
proteins were then subjected to SDS-PAGE, and Aurora A, S6K1, 4E-BP1, and 
their phosphorylation were measured by immunoblotting using specific 
antibodies. 
 
B. The relative levels of Aurora A proteins from three independent experiments 
are shown in the histogram. 
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4.13  mTOR-mediated destruction of Aurora A is not completely dependent 
on APC activator Cdh1 
It is well-known that Cdh1, also called homolog of Drosophila fizzy-related 
gene 1 or FZR1, functions as an activator of APC/C at later mitosis (anaphase) 
and subsequent G1 to destroy Aurora A protein [111] [159]. To examine the 
mechanism of mTOR action, I asked whether Cdh1 is involved in mTOR 
mediated Aurora A destruction. To answer this question, I first examined Cdh1 
specificity and efficiency of shRNAs. From five shRNAs which target different 
coding regions of Cdh1 genes, I identified that three shRNAs effectively knocked 
down Cdh1 expression (Figure 4.13.1). By blast search, two shRNAs, #3 and #4, 
have no or only minimal off-target binding. Thus, these two shRNAs were 
selected to use in the following studies.  
To look directly at the mechanism of APC/cdh1-dependent, mTOR-
mediated Aurora A degradation, I knocked down Cdh1 by transducing lenti-viral 
Cdh1 shRNAs to the cells for 60 hours then treating with or without mTOR 
inhibitor KU36794 for additional 12 hours. The immunoblotting showed in Figure 
4.13.2 that Aurora A accumulated in the Cdh1 knocked down sample and Aurora 
A level was diminished in the mTOR suppressed cells, as expected. However, 
knocking down Cdh1 did not completely prevent Aurora A degradation from 
mTOR inhibition. Considering Cdh1 only interacts with the D-box of Aurora A, I 
reasoned that additional Aurora A sequence(s) or signaling pathway(s) may be 
involved in the protein destruction. 
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Figure 4.13.1  Efficiency of Cdh1 shRNAs 
 
Five individual lenti-viral Cdh1 shRNAs, which target different coding regions of 
the Cdh1gene, were generated, see Material and Method. HeLa cells were 
transduced with 0.5 ml of individual lenti-viruses that contain specific shRNAs. At 
72 hours post transduction, the cellular extracts were harvested and subject to 
immunoblotting analysis using antibodies that specifically recognize Cdh1 
protein. GAPDH was used as a loading control. 
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Figure 4.13.2  mTOR-mediated degradation of Aurora A is not completely 
dependent on APC activator Cdh1. 
 
A. Knockdown Cdh1 was conducted by transduction of lenti-viral shRNAs 
indicated above in HeLa cells. At 60 hours post transduction, the cells were 
treated with mTOR inhibitor KU36794 1μM or vehicle DMSO for 12 hours. Cell 
lysates were harvested and equal amounts of the proteins were then subjected to 
SDS-PAGE, Cdh1, Aurora A, S6K1, 4E-BP1, and 4E-BP1 T37/46 were measured 
by immunoblotting using specific antibodies. 
 
B. The data from three independent experiments was pooled and shown as 
mean ± standard deviation. 
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4.14  Suppression of PP2A phosphatase rescues mTOR-mediated Aurora A 
destruction 
Protein phosphatase 2A (PP2A) is a key enzyme for metaphase-
anaphase transition in mammalian cells [160-164]. PP2A was found to co-
localize with and interacted with Aurora A in the centrosomes [165, 166] during 
interphase [167, 168] as well as mitosis [169] and is responsible for Aurora A 
serine 51 (S51) phosphorylation status [75]. Therefore I hypothesized that mTOR 
regulates Aurora A degradation via PP2A. To test this possibility, I used a 
serine/threonine phosphatase inhibitor okadaic acid (OA), which at low 
concentration preferentially inhibits the PP2A activity [164, 170]. In this 
experiment, HeLa cells were pre-treated with OA 1 nM for 15 minutes prior to 
exposure to KU63794 for an additional hour. The immunoblotting showed at 
Figure 4.14 that inhibition of mTOR activity reduced the amount of Aurora A, 
compared to the vehicle control, consistent with my previous data. Importantly, 
treating cells with OA prior to addition of KU63794 rescued Aurora A proteins 
from degradation, supporting my hypothesis that action of mTOR in stabilizing 
Aurora A protein results from inhibition of PP2A phosphatase activity. 
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Figure 4.14  Inhibition of phosphatase PP2A rescues mTOR-mediated 
Aurora A destruction. 
 
A. HeLa cells were pre-treated with PP2A inhibitor OA 1 nM for 15 minutes prior 
to exposure to mTOR inhibitor KU63794 1μM or vehicle DMSO for 1 hour. Cell 
lysates were harvested and equal amounts of the proteins were then subjected to 
SDS-PAGE, Aurora A, S6K1 and its residue T389 phosphorylation were 
measured by immunoblotting assays using specific antibodies. 
 
B. Graph of Aurora A protein levels from three experiments. 
 
 
4.15  PP2A substrate Aurora-A Ser51 is responsive to mTOR-mediated 
protein destruction 
 It was reported that in Xenopus either substitution of S53 (corresponding 
to human S51) phosphorylation at N- terminal activation box (A-box) by a residue 
mimicking phosphorylation or a single point mutation in the degradation box (D-
box) is sufficient to stabilize Xenopus Aurora A. The former mutation presumably 
prevents the unmasking of the D-box by dephosphorylation of the A-box [92]. It 
appears to take place in mammalian cells in vivo. Horn, et al. showed that PP2A 
dephosphorylates S51 in the A-box, leading to Aurora A degradation [119]. My 
data described above support the idea that mTOR inhibits PP2A activity to 
stabilize Aurora A protein. Thus, I reasoned that mTOR might affect the 
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phosphorylation status of Aurora A S51 and influence the protein stability. To test 
this possibility, I first transiently transfected constructs expressing either wild type 
(WT) Aurora A or one of two mutants, Aurora A S51A (non-phosphorylated) and 
Aurora A S51D (phosphomimic), and compared their sensitivities to degradation 
under mTOR inhibition. Consistent with the results reported previously, Aurora A 
S51A mutant expression was lower than that of Aurora A S51D or WT, as judged 
by the immunoblotting (Figure 4.15). This may be because the S51A mutant is 
unable to protect the D-box of the kinase from APC/C proteasome-mediated 
degradation. 
Next, I examined whether mTOR controls Aurora A destruction via 
phosphorylation of Aurora A S51. HeLa cells described above (transfected with 
AURKA mutants for 24 hours) were treated with or without mTOR inhibitor 
KU63794 for an additional 2 hours. Interestingly, inhibition of mTOR accelerated 
Aurora A degradation in the S51A mutant cells, but not in the S51D (Figure 4.15). 
This indicates that mTOR elevates phosphorylation level of S51 in the 
“activation-box” of Aurora A, which dictates Aurora A sensitivity to proteasomal 
degradation. 
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Figure 4.15  PP2A substrate Aurora A Ser51 is responsive to mTOR-
mediated protein destruction 
 
A.Domains of Aurora A protein 
 
B.HeLa cells were transiently transfected with Aurora A WT or 
unphosphorylatable S51A or phosphomimetic S51D mutant for 24 hours, then 
treated with or without mTOR inhibitor KU63794 for 2 hours. The cellular lysates 
were subjected to SDS-PAGE, and the protein levels of exogenous Aurora A 
(Flag-Aurora A) and endogenous 4E-BP1 and GAPDH were determined by 
immunoblotting assays.  
 
C. Aggregate data from three independent experiments is shown. 
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4.16 Summary  
 
Figure 4.16 Model of mTOR/PP2A/Aurora A Ser15 axis for Aurora A protein 
stability  
 
mTOR controls Aurora A destruction by inactivating PP2A, elevating the 
phosphorylation level of Ser51 in the “activation-box” of Aurora A, preventing the 
unmasked D box from APC/C Cdh1-mediated proteasome degradation. Thus, 
mTOR enhances stability of Aurora A protein.  
 
In this study, I demonstrated that suppressing mTOR activity impacted the 
G2-M transition and reduced levels of M-phase kinases, Aurora A. mTOR 
inhibitors did not affect Aurora-A mRNA levels. However, translational reporter 
constructs showed that mRNA containing a short, simple 5’-untranslated region, 
rather than a complex structure, is more responsive to mTOR inhibition. mTOR 
inhibitors decreased Aurora A protein amount whereas blocking proteasomal 
degradation rescues this phenomenon, revealing that mTOR affects Aurora A 
protein stability. Inhibition of protein phosphatase, PP2A, a known mTOR 
substrate and Aurora A partner, restored mTOR-mediated Aurora A abundance. 
Finally, a non-phosphorylatable Aurora A mutant was more sensitive to 
destruction in the presence of mTOR inhibitor. These data strongly support the 
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notion that mTOR controls Aurora A destruction by inactivating PP2A and 
elevating the phosphorylation level of Ser51 in the “activation-box” of Aurora A, 
which dictates its sensitivity to proteasomal degradation. 
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4.17 Discussion 
mTOR is a master regulator of cell metabolism, growth, proliferation and 
survival [9, 39, 171]. The mechanisms of mTOR actions are mainly through 
transcription, translation and protein stability. While these mTOR functions have 
been well-documented in the regulation of the G1 phase of the cell cycle, 
whether/how mTOR regulates the G2/M phases are just beginning to be 
understood.  
During my early studies, I demonstrated that mTOR-induced 
phosphorylation of S6K1 and 4E-BP1 starts to increase in S phase and peaks at 
G2/M. During the course of my research, other investigators also observed that 
mTOR downstream kinase S6K1 and its substrate S6 were highly 
phosphorylated during lymphoma cell mitosis [82, 172]. The 
immunohistochemistry staining in cancer cells revealed that Serine 2481 
autophosphorylation of mTOR couples with chromosome condensation and 
segregation during mitosis in breast cancer core biopsies [173]. TSC2 maintains 
nuclear envelope structure and controls cell division [174]. All these findings 
supported my hypothesis that mTOR may regulates mitotic progression.  
Using mTOR inhibitors as a tool, I demonstrated that mTOR impacts 
mitotic progression by decreasing mitotic marker phosphor-Histone H3 and 
reducing 4N chromosomal population in mitosis. This is consistent with a recent 
work by Ramirez-Valle and his colleagues that showed mitotic raptor promotes 
G2/M transition; overexpression of a raptor phosphorylation mutant caused G2 
accumulation in HaCaT cells [175, 176]. 
 111 
 
However, which mitotic kinase mediated mTOR action and how it is 
regulated by mTOR remains to be uncovered. In my pilot study, immunoblotting 
showed Aurora A is most obviously decreased, among several mitotic kinases, 
following inhibition of mTOR. Considering its critical roles in mitosis progression 
and tumorigenesis [120, 177-179], Aurora A was selected as a target for mTOR 
regulation in my study.  
 
4.17.1  mTOR does not affect Aurora A transcription. 
One of the known mechanisms for Aurora A overexpression in cancers is 
through RNA transcriptional up-regulation [94, 180]. Since mTOR was reported 
to regulate transcription [20], I examined mTOR effects on AURKA mRNA levels. 
Quantitative PCR showed that AURKA mRNA levels were not alternated by 
mTOR inhibitor rapamycin. Consistently, the transcripts also remain unchanged 
in the cells treated with three additional ATP-competitive mTOR kinase inhibitors. 
These data strongly suggest that mTOR does not affect Aurora A transcription.  
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4.17.2  Does a short and simple or long and complex, mRNA structure 
preferentially regulated by mTOR? 
Genomic analysis revealed that 35-94% of cancers undergo alterative 
splicing, and lots of cancer-specific transcript variants were identified [181, 182]. 
Chien-Hsien Lai, et al. reported that EGF mediated translational regulation of 
AURKA contains non-coding exons I and II within the 5’ UTR [95]. As shown in 
Figure 1.6, AURKA 5’UTRs that contain exon II are longer and possess an 
upstream ORF that is out of frame with the main initiating ATG. Thus it appeared 
that a long, complex mRNA with a secondary structure might be sensitive to 
mTOR regulation.  
Recently, Thoreen et al. (2012) performed transcriptome-wide profiling in 
mouse embryonic fibroblasts cells to determine the effect of mTOR inhibition on 
mRNA translation (ribosome loading) [69]. They found no evidence for a 
previously postulated theory that mTORC1 regulates the translation of mRNAs 
with highly structured and complex 5’ untranslated regions. These controversial 
results raised a question whether short or longer mRNAs are sensitive to 
mTORC1 regulation. In ours hands, the luciferase assays consistently showed 
that a short and simple (splice variant 6), rather than long and complex (splice 
variant 5), 5’-UTR of AURKA is sensitive to mTOR signaling, supportive of the 
study by Thoreen and colleagues. 
Since the variant 6 is sensitive to mTOR manipulation, it would be 
interesting to identify specific types of cancers which predominantly express this 
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or other short versions of AURKA UTR. This information may provide strategy 
chemotherapy against certain tumors. 
As the variant 6 is a minor expressed form of Aurora A mRNA in HeLa 
cells, additional pathway(s) must be required for mTOR regulation of Aurora A as 
total Aurora A proteins were dramatically reduced by mTOR inhibition.  
 
4.17.3  How does mTOR affect Aurora A protein stability?  
It is well known that Aurora A protein degradation is through APC/C-
mediated ubiquitination-proteasome pathway. I therefore questioned whether 
mTOR mediated Aurora A stability via this pathway. Using protein synthesis 
inhibitor CHX and proteasome inhibitor MG132, I found that suppression of 
proteasome activity prevents mTOR-mediated Aurora A destruction, implying that 
mTOR is involved in the regulation of Aurora A protein stability. Since Aurora A is 
reported to be ubiquitinated by APC in order to be recognized by the 26S 
proteasome system for destruction, it would be interesting to examine the 
ubiquitination status of Aurora A under mTOR inhibition to further confirm this 
finding. An experimental design for this purpose will be discussed in the “Future 
Direction” section.  
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4.17.4  How does PP2A involve in mTOR - mediated Aurora A protein 
stability ? 
Firstly, does mTOR may regulate Aurora A degradation via PP2A or it 
might just be that PP2A regulates an essential step in Aurora A degradation, 
independent of mTOR? To answer this question, exogenous S51 mutants were 
expressed in HeLa cells that were pre-treated with PP2A inhibitor, OA prior to 
exposing cells to mTOR inhibitor. However, a technical challenge was that these, 
exogenous S51A or S51D mutants require a 18-24 hours period time post 
transfection, to become expressed while OA can only be administered to cells for 
a short time, less than 2 hours. 
It is known that mTOR inhibits PP2A activity while treatment of cells with 
rapamycin stimulated PP2A activity [183]. The mechanism of mTOR action to 
PP2A is believed through Tap42p in Saccharomyces cerevisiae (TAP42) and 
alpha4 in mammalian cells). In yeast, Tor regulates PP2A by phosphorylating 
TAP42, causing a redistribution of the PP2A catalytic subunit into a complex with 
TAP42 and away from the normal A and B regulatory subunits [184]. The binding 
of PP2A toTAP42 leads to the inhibition of PP2A activity or a dramatic change in 
its substrate specificity [185]. In mammalian cells, the pool of PP2A was found 
associated with alpha 4. Although a small portion of the cellular pool of PP2A is 
present in a complex with alpha4, the latter plays a crucial role to affect PP2A 
activity [186]. Using PP2A inhibitor OA, I demonstrated that PP2A inhibition 
impaired the mTOR-dependent Aurora A destruction, indicating that mTOR 
 115 
 
mediated Aurora A stability via a dephosphorylation pathway and that PP2A may 
be involved in this event. 
 Viallet et al. reported that PP2A and Aurora A proteins are co-localized at 
the centrosome during mitosis and following G1 phase [119]. PP2A directly 
dephosphorylates Aurora A Ser51 and triggers Aurora A degradation [119] 
whereas reducing PP2A enzymatic activity with OA stabilizes Aurora A protein. In 
the current study, based on the finding that inhibition of mTOR accelerates 
degradation of non-phosphorylatable Aurora A S51A mutant, I found that mTOR 
prevent Aurora A S51 dephosphorylation, This conclusion is further supported by 
the observation that the phosphor-mimic S51D mutant restored the Aurora A 
protein levels.  
By 2007, studies had shown that in Xenopus either substitution of S53 
(corresponding to human Aurora A S51) of the A box by a residue mimicking 
phosphorylation or a single point mutation in the degradation box is sufficient to 
stabilize Xenopus and mammalian Aurora A [109, 119]. The former mutation 
presumably prevents the unmasking of the D-box by dephosphorylation of the A-
box. As the D-box is involved in recognition by the APC/C Cdh1 complex, its 
alteration also prevents degradation. My data demonstrated that mTOR is an 
upstream regulator of Aurora A, and suggest that mTOR controls Aurora A S51 
phosphorylation, perhaps indirectly, and consequently modulates Aurora A 
protein stability. While mTOR regulated Aurora A dephosphorylation, the kinase 
that catalyzes Aurora A S51 phosphorylation is unknown. It would also be 
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interesting in future to investigate the role of Aurora A S51 in the cell cycle 
control. 
Recent studies by others have shown that protein phosphatase PP6 also 
interacts with alpha4 and mimics PP2A activity during mitosis [187-191]. PP6 
acts as an Aurora A T-loop phosphatase against known Aurora A activator 
targeting protein for Xenopus kinesin-like protein 2 (TPX2), a key protein required 
for targeting Aurora A to the mitotic spindle [187, 192]. Depletion of PP6 catalytic 
subunit with RNAi led to abnormal chromosome segregation in anaphase, which 
was favorable to stabilize Aurora A interacting with its activator TPX2 [187]. The 
latter not only stimulates autophosphorylation at T loop residue Thr288, 
autoactivation of the enzyme [193], and targets Aurora A to the spindle, but also 
affects Aurora A protein stability [194]. These studies suggest that PP6 affects 
activity and stability of Aurora A. 
More interestingly, mTOR seems to be associated with PP6. In yeast, and 
probably in higher eukaryotes, mTOR signals through Tap42p/alpha 4 to regulate 
protein phosphatases. Phosphorylating Tap42p/alpha 4, mTOR abrogates 
dephosphorylation of the downstream effectors by PP2A and/or PP6, resulting in 
their increased phosphorylation and activity [195]. Thus, it would be interesting to 
examine whether PP6 is also involved in mTOR-mediated Aurora A protein 
activity and stability. This is further discussed in the “future direction” section. 
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4.17.5  Why would mTOR stabilize Aurora A during M phase? 
mTOR stabilization of Aurora A perhaps helps maintain the mitotic spindle 
checkpoint during the cell cycle. This is supported by Astrinidis’ study [196] on 
how TSC2 loss (equivalent to mTOR activation) leads to regulation of mitosis and 
might be tightly regulated by feedback from M phase kinases PLK1. It was shown 
that Hamartin (TSC1 product) negatively regulates the protein levels of PLK1 in 
TSC1/2 mouse embryonic fibroblasts and increases the number of centrosomes. 
Thus TSC1/2 and mTOR signaling may regulate mitosis checkpoint during the 
cell cycle.  
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In summary, this study showed that mTOR activity remains high at G2/M 
phase of the cell cycle. Inhibition of mTOR impacted mitosis progression. This 
study demonstrated that mTOR regulates Aurora A mitotic protein kinase 
expression and protein stability. Depletion of mTOR activity did not affect Aurora-
A message RNA levels. Suppressing mTOR modestly inhibited Aurora A mRNA 
translation, particularly the less-abundant short 5’UTR variant 6. mTOR controls 
Aurora A stability by inactivating PP2A and elevating the phosphorylation level of 
Ser51 in the “activation-box” of Aurora A, which dictates its sensitivity to 
proteasomal degradation. This is the first report demonstrating that mTOR 
signaling regulates Aurora A protein expression and stability and provides a 
better understanding of how mTOR regulates mitotic kinase expression and 
coordinates cell cycle progression. 
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FUTURE DIRECTIONS 
It was previously reported that PP6 interacts with Aurora A at the 
centrosome and might affect both the activity and stability of Aurora A [187].  
Since mTOR may additionally influence PP6 activity [195], it would be interesting 
to examine whether PP6 is involved in mTOR-mediated Aurora A destruction. 
Technically, it is suitable to carry out further study using our current model 
system since all the PP6 subunits exist in HeLa cells [187]. Use of RNAi 
approach to knock down PP6 mRNAs, in the presence or absence of mTOR 
inhibitor, would help us to answer this question.  
Since Aurora A splice variant 6 is sensitive to mTOR inhibition, then the 
translation of Aurora A in tumor cells expressing each variant with a short 5’UTR 
that lacks uORFs (variants 2, 4, 6) may be suppressed by mTOR inhibitors. It 
would be interesting to test this hypothesis as it may identify a means of 
screening tumors for sensitivity to treatment with mTOR kinase inhibitors. 
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APPENDIX  PCR PRIMERS 
 
  
Primer           Sequence
Aurka1rev 5’-TGGAGTGAGACCCTCTAGCTGTA
Aurka2rev 5’-CCATGATGCCTCTAGCTGTAAT
Aurka3rev 5’-TGGAGTGAGACCCCGTCGGCTC
Aurka4rev 5’-CCATGATGCCCGTCGGCTCCCA
Aurka5rev 5’-TGGAGTGAGACCCTGCGACCCA
Aurka6rev 5’-GATCGGTCCATGATGCCTGCGA
Aurka1fw d 5'-GTCAACCAATCACAAGGCAGC
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